KEMBAR78
Stability Testing Guide | PDF | Medicine | Patient Safety
0% found this document useful (0 votes)
197 views23 pages

Stability Testing Guide

This document provides guidelines for stability testing of active pharmaceutical ingredients and finished pharmaceutical products. It outlines the objectives, scope, and general principles of stability testing. The goals of stability testing are to confirm the quality and characteristics of pharmaceuticals when exposed to various environmental factors like heat, moisture, light, and vibration over time, and to make recommendations regarding storage conditions, retesting periods, and expiration dates.

Uploaded by

Rowaida
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
197 views23 pages

Stability Testing Guide

This document provides guidelines for stability testing of active pharmaceutical ingredients and finished pharmaceutical products. It outlines the objectives, scope, and general principles of stability testing. The goals of stability testing are to confirm the quality and characteristics of pharmaceuticals when exposed to various environmental factors like heat, moisture, light, and vibration over time, and to make recommendations regarding storage conditions, retesting periods, and expiration dates.

Uploaded by

Rowaida
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 23

‫ﺍﻝﺠﻤﻬﻭﺭﻴﺔ ﺍﻝﻌﺭﺒﻴﺔ ﺍﻝﺴﻭﺭﻴﺔ‬

‫ﻭﺯﺍﺭﺓ ﺍﻝﺼﺤﺔ‬

‫ﺩﻝﻴل ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺜﺒﺎﺕ‬

‫‪GUIDELINE ON STABILITY‬‬
‫‪TESTING‬‬

‫ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺜﺒﺎﺕ ﻝﻠﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﻭﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ‬


‫ﺍﻝﺼﻴﺩﻻﻨﻴﺔ ﺍﻝﺠﺎﻫﺯﺓ‬

‫‪STABILITY TESTING OF‬‬


‫‪EXISTING ACTIVE SUBSTANCES‬‬
‫‪AND RELATED FINISHED‬‬
‫‪PHARMACEUTICAL PRODUCTS‬‬
‫ﺍﻝﺩﻝﻴل ﻫﻭ ﺘﺭﺠﻤﺔ ﻝﻠﻭﺜﻴﻘﺔ ﺍﻝﺼﺎﺩﺭﺓ ﻋﻥ ﺍﻝﻭﻜﺎﻝﺔ ﺍﻷﻭﺭﻭﺒﻴﺔ ﻝﺘﻘﻴﻴﻡ ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺩﻭﺍﺌﻴﺔ‬
‫‪(EMEA) The European Agency for the Evaluation of Medicinal Products‬‬

‫ﻭﺯﺍﺭﺓﺍﻝﺼﺤﺔ‪ -‬ﺩﻤﺸﻕ ‪٢٠٠٦‬‬

‫‪١‬‬
‫ﺩﻝﻴل ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺜﺒﺎﺕ‬
GUIDELINE ON STABILITY TESTING

‫ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺜﺒﺎﺕ ﻝﻠﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﻭﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺠﺎﻫﺯﺓ‬


STABILITY TESTING OF EXISTING ACTIVE
SUBSTANCES AND RELATED FINISHED PRODUCTS
‫ﺍﻝﺩﻝﻴل ﻫﻭ ﺘﺭﺠﻤﺔ ﻝﻠﻭﺜﻴﻘﺔ ﺍﻝﺼﺎﺩﺭﺓ ﻋﻥ ﺍﻝﻭﻜﺎﻝﺔ ﺍﻷﻭﺭﻭﺒﻴﺔ ﻝﺘﻘﻴﻴﻡ ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺩﻭﺍﺌﻴﺔ‬
(EMEA) The European Agency for the Evaluation of Medicinal Products

٢
‫‪ -١‬ﻤﻘﺩﻤﺔ ‪INTRODUCTION‬‬

‫‪ ١-١‬ﺍﻝﻬﺩﻑ ﻤﻥ ﻫﺫﺍ ﺍﻝﺩﻝﻴل ‪Objective of the Guideline‬‬

‫ﻴﺴﺘﺨﺩﻡ ﻫﺫﺍ ﺍﻝﺩﻝﻴل ﻝﻠﻤﻭﺍﺩ ﺍﻷﻭﻝﻴﺔ ﺍﻝﻔﻌﺎﻝﺔ ﻭﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺠﺎﻫﺯﺓ ﺫﺍﺕ ﺍﻝﻌﻼﻗﺔ‬
‫ﻭﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﻨﺒﺎﺘﻴﺔ ﺍﻝﺩﻭﺍﺌﻴﺔ ﺇﻻ ﺃﻨﻬﺎ ﻻﺘﺸﻤل ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺼﻴﺩﻻﻨﻴﺔ‬
‫ﺍﻝﻤﻭﺴﻭﻤﺔ ﺸﻌﺎﻋﻴﺎ ﻭﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺤﻴﻭﻴﺔ ﻭﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﻤﺼﻨﻌﺔ ﺒﻁﺭﻴﻘﺔ‬
‫ﺍﻝﻬﻨﺩﺴﺔ ﺍﻝﻭﺭﺍﺜﻴﺔ‪.‬‬

‫‪ ٢-١‬ﻤﺠﺎل ﻫﺫﺍ ﺍﻝﺩﻝﻴل ‪Scope of the Guideline‬‬

‫ﻴﺒﻴﻥ ﻫﺫﺍ ﺍﻝﺩﻝﻴل ﺍﻝﻤﻌﻠﻭﻤﺎﺕ ﺍﻝﺘﻲ ﺘﻘﺩﻡ ﻓﻲ ﻤﻠﻔﺎﺕ ﺘﺴﺠﻴل ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ‬
‫ﻭﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺼﻴﺩﻻﻨﻴﺔ ﺫﺍﺕ ﺍﻝﻌﻼﻗﺔ‪.‬‬

‫‪ ٣-١‬ﺍﻝﻤﺒﺎﺩﻱﺀ ﺍﻝﻌﺎﻤﺔ ‪General Principles‬‬

‫ﺇﻥ ﺍﻝﻬﺩﻑ ﻤﻥ ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺜﺒﺎﺕ ﻫﻭ ﺘﺄﻜﻴﺩ ﻨﻭﻋﻴﺔ ﻭﺠﻭﺩﺓ ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ‬


‫ﻭﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺼﻴﺩﻻﻨﻴﺔ ﺫﺍﺕ ﺍﻝﻌﻼﻗﺔ ﻋﻨﺩ ﺘﻌﺭﻀﻬﺎ ﻝﻠﻌﻭﺍﻤل ﺍﻝﺒﻴﺌﻴﺔ ﺍﻝﻤﺨﺘﻠﻔﺔ‬
‫ﺍﻝﻤﺫﻜﻭﺭﺓ ﺃﻋﻼﻩ ‪ ،‬ﻭﺘﻬﺩﻑ ﺃﻴﻀﺎ ﺇﻝﻰ ﻭﻀﻊ ﺍﻝﻤﻘﺘﺭﺤﺎﺕ ﺍﻝﺨﺎﺼﺔ ﺒﻅﺭﻭﻑ‬
‫ﺍﻝﺘﺨﺯﻴﻥ ‪ ،‬ﺇﻋﺎﺩﺓ ﺍﻝﻔﺤﺹ ﻭﺘﺤﺩﻴﺩ ﻤﺩﺓ ﺼﻼﺤﻴﺔ ﺍﻷﺩﻭﻴﺔ‪.‬‬
‫ﺇﻥ ﺃﻜﺜﺭ ﺍﻝﻌﻭﺍﻤل ﺍﻝﺘﻲ ﺘﺴﺎﻫﻡ ﻓﻲ ﺘﺤﻁﻡ ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺼﻴﺩﻻﻨﻴﺔ ﻫﻲ ‪:‬‬
‫ﺍﻝﻌﻭﺍﻤل ﺍﻝﺒﻴﺌﻴﺔ ﻜﺎﻹﺸﻌﺎﻉ ‪ ،‬ﺍﻝﺤﺭﺍﺭﺓ ‪ ،‬ﺍﻝﺭﻁﻭﺒﺔ ‪ ،‬ﺍﻝﻀﻭﺀ ‪ ،‬ﺍﻷﻭﻜﺴﺠﻴﻥ‬
‫ﻭﺍﻝﻤﺅﺜﺭﺍﺕ ﺍﻝﻔﻴﺯﻴﺎﺌﻴﺔ) ﺍﻻﻫﺘﺯﺍﺯ‪ ،‬ﺍﻝﺘﺠﻤﻴﺩ (‪.‬‬

‫‪ -١‬ﻋﻭﺍﻤل ﻤﺭﺘﺒﻁﺔ ﺒﺎﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺼﻴﺩﻻﻨﻴﺔ ‪:‬‬


‫ﺃ‪ -‬ﺍﻝﺨﻭﺍﺹ ﺍﻝﻔﻴﺯﻴﺎﺌﻴﺔ ﻭﺍﻝﻜﻴﻤﻴﺎﺌﻴﺔ ﻝﻠﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﻭﺍﻝﺴﻭﺍﻏﺎﺕ‪.‬‬
‫ﺍﻝﺼﻴﻐﺔ ﺍﻝﺩﻭﺍﺌﻴﺔ ﻭﺍﻝﺘﺭﻜﻴﺏ‪.‬‬ ‫ﺏ‪-‬‬
‫ﻁﺭﻕ ﺍﻝﺘﺼﻨﻴﻊ‪.‬‬ ‫ﺕ‪-‬‬
‫‪ -٢‬ﻁﺒﻴﻌﺔ ﻤﻭﺍﺩ ﺍﻝﺘﻌﺒﺌﺔ ﻭﺍﻝﺘﻐﻠﻴﻑ ﻝﻠﻤﺴﺘﺤﻀﺭ‪.‬‬

‫‪٣‬‬
‫ﺍﻝﺩﻻﺌل ‪Guidelines‬‬ ‫‪-٢‬‬

‫‪ ١-٢‬ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ‪Active Substance‬‬


‫‪ ١,١,٢‬ﻋﺎﻡ ‪General‬‬

‫ﺇﻥ ﺍﻝﻤﻌﻠﻭﻤﺎﺕ ﻋﻥ ﺜﺒﺎﺕ ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﺘﻌﺘﺒﺭ ﺠﺯﺀ ﺃﺴﺎﺴﻲ ﻓﻲ ﻤﻔﻬﻭﻡ ﺘﻘﻴﻴﻡ‬
‫ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ‪.‬‬
‫ﺘﻁﻠﺏ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﺠﻤﻴﻊ ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﺍﻝﺘﻲ ﻝﻡ ﺘﺫﻜﺭ ﻓﻲ ﺩﺴﺎﺘﻴﺭ ﺍﻷﺩﻭﻴﺔ‬
‫ﺍﻝﻌﺎﻝﻤﻴﺔ ‪.‬‬
‫ﺃﻤﺎ ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﺍﻝﺘﻲ ﺘﻡ ﻭﺼﻔﻬﺎ ﻓﻲ ﺩﺴﺎﺘﻴﺭ ﺍﻷﺩﻭﻴﺔ ﺍﻝﻌﺎﻝﻤﻴﺔ ﻭﺍﻝﺘﻲ ﺘﻐﻁﻲ ﻤﻭﺍﺩ‬
‫ﺍﻝﺘﺨﺭﺏ ﻭﺫﻜﺭ ﻝﻬﺎ ﺤﺩﻭﺩ ﻤﻨﺎﺴﺒﺔ ﻭﻓﻲ ﻨﻔﺱ ﺍﻝﻭﻗﺕ ﻝﻡ ﻴﺤﺩﺩ ﻝﻬﺎ ﺘﺎﺭﻴﺦ ﺇﻋﺎﺩﺓ‬
‫ﺍﻝﺘﺤﻠﻴل ﻓﺈﻨﻪ ﻴﻤﻜﻥ ﻗﺒﻭل ﺇﺤﺘﻤﺎﻝﻴﻥ‪:‬‬
‫ﺃ‪ -‬ﻋﻠﻰ ﻤﻘﺩﻡ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﺃﻥ ﻴﺒﻴﻥ ﺒﺄﻥ ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﺘﺘﻁﺎﺒﻕ ﻤﻊ ﺍﻝﻨﺹ‬
‫ﺍﻝﺩﺴﺘﻭﺭﻱ ﻤﺒﺎﺸﺭﺓ ﻗﺒل ﺘﺼﻨﻴﻌﻬﺎ ﻓﻲ ﺍﻝﻤﺴﺘﺤﻀﺭ ﺍﻝﻨﻬﺎﺌﻲ‪ .‬ﻓﻲ ﻫﺫﻩ ﺍﻝﺤﺎﻝﺔ‬
‫ﻻﻴﺤﺘﺎﺝ ﺍﻝﻤﺼﻨﻊ ﺃﻥ ﻴﻘﺩﻡ ﺩﺭﺍﺴﺎﺕ ﺜﺒﺎﺕ ‪.‬‬
‫ﻋﻠﻰ ﻤﻘﺩﻡ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﺃﻥ ﻴﻀﻊ ﺘﺎﺭﻴﺦ ﺇﻋﺎﺩﺓ ﺍﻝﺘﺤﻠﻴل ﺒﺎﻻﺴﺘﻨﺎﺩ ﻋﻠﻰ‬ ‫ﺏ‪-‬‬
‫ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‪.‬‬
‫ﻓﻲ ﺤﺎﻝﺔ ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺩﻭﺍﺌﻴﺔ ﺍﻝﻨﺒﺎﺘﻴﺔ ﻭﻤﻭﺍﺩﻫﺎ ﺍﻝﻔﻌﺎﻝﺔ ﻓﺈﻨﻬﺎ ﻴﺠﺏ ﺃﻥ ﺘﻜﻭﻥ‬
‫ﻤﻁﺎﺒﻘﺔ ﻝﻠﻤﻭﺍﺼﻔﺎﺕ ﻗﺒل ﺍﻻﺴﺘﻌﻤﺎل) ﻤﺜل ﻗﺒل ﺍﻻﺴﺘﺨﻼﺹ(‪.‬‬

‫‪ ٢,١,٢‬ﺍﻝﺩﺭﺍﺴﺎﺕ ﺍﻝﺘﺸﺩﺩﻴﺔ ‪Stress Testing‬‬

‫ﺇﻥ ﺍﻝﺩﺭﺍﺴﺎﺕ ﺍﻝﺘﺸﺩﺩﻴﺔ ﻝﻠﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﻴﻤﻜﻥ ﺃﻥ ﺘﺴﺎﻋﺩ ﻓﻲ ﺘﺤﺩﻴﺩ ﻤﻭﺍﺩ ﺍﻝﺘﺨﺭﺏ‬
‫ﺍﻝﻤﺤﺘﻤﻠﺔ‪ ،‬ﻭﺍﻝﺘﻲ ﺒﺩﻭﺭﻫﺎ ﺘﺴﺎﻋﺩ ﻓﻲ ﻤﻌﺭﻓﺔ ﺁﻝﻴﺔ ﺍﻝﺘﺨﺭﺏ ﻭﺍﻝﺜﺒﺎﺕ ﺍﻝﺤﻘﻴﻘﻲ‬
‫ﻝﻠﻤﺭﻜﺏ ﻭﺍﻝﺘﺤﻘﻕ ﻤﻥ ﻗﻭﺓ ﻤﺅﺸﺭﺍﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺫﻜﻭﺭﺓ ﻓﻲ ﻁﺭﻕ ﺍﻝﺘﺤﻠﻴل‬
‫ﺍﻝﻤﺴﺘﺨﺩﻤﺔ‪.‬‬
‫ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺘﺸﺩﺩﻴﺔ ﻫﻲ ﻋﺎﺩﺓ ﻏﻴﺭ ﻀﺭﻭﺭﻴﺔ ﻓﻲ ﺤﺎﻝﺔ ﺍﻷﺩﻭﻴﺔ ﺍﻝﻨﺒﺎﺘﻴﺔ‬
‫ﻭﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺩﻭﺍﺌﻴﺔ ﺍﻝﻨﺒﺎﺘﻴﺔ‪.‬‬

‫ﻴﻤﻜﻥ ﺍﺴﺘﺨﺩﺍﻡ ﺍﻝﻁﺭﻕ ﺍﻝﺘﺎﻝﻴﺔ ﻝﻠﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﺍﻝﻨﺒﺎﺘﻴﺔ‪:‬‬


‫ﺃ‪ -‬ﻋﻨﺩ ﺫﻜﺭ ﺍﻝﻤﺎﺩﺓ ﻓﻲ ﺩﺴﺘﻭﺭ ﺍﻷﺩﻭﻴﺔ ﻭﺘﺤﻘﻴﻘﻬﺎ ﻝﻜﺎﻓﺔ ﺍﻝﻤﺘﻁﻠﺒﺎﺕ ﺍﻝﺩﺴﺘﻭﺭﻴﺔ‬
‫ﻋﻨﺩﻫﺎ ﻻﻴﻁﻠﺏ ﺘﻘﺩﻴﻡ ﺒﻴﺎﻨﺎﺕ ﺘﺘﻌﻠﻕ ﺒﻤﻨﺘﺠﺎﺕ ﺍﻝﺘﺨﺭﺏ ﺇﺫﺍ ﺫﻜﺭﺕ ﻓﻲ ﺍﻝﺩﺴﺘﻭﺭ‬
‫ﺒﺈﺴﻡ ﺘﺤﺕ ﻋﻨﻭﺍﻥ ﺇﺨﺘﺒﺎﺭ ﺍﻝﻨﻘﺎﻭﺓ ﺃﻭ ﺍﻝﻘﺴﻡ ﺍﻝﻤﺘﻌﻠﻕ ﺒﺎﻝﺸﻭﺍﺌﺏ‪.‬‬
‫ﺇﺫﺍ ﻜﺎﻨﺕ ﺍﻝﻤﺎﺩﺓ ﺍﻝﺩﻭﺍﺌﻴﺔ ﻏﻴﺭ ﻤﻨﺼﻭﺹ ﻋﻠﻴﻬﺎ ﻓﻲ ﺩﺴﺘﻭﺭ ﺍﻷﺩﻭﻴﺔ‬ ‫ﺏ‪-‬‬
‫ﻋﻨﺩﻫﺎ ﻴﻭﺠﺩ ﺨﻴﺎﺭﻴﻥ‪:‬‬

‫‪٤‬‬
‫‪ -‬ﻴﻤﻜﻥ ﻗﺒﻭل ﺘﻘﺩﻴﻡ ﺒﻴﺎﻨﺎﺕ ﻨﺸﺭﺕ ﻓﻲ ﺍﻝﻤﺭﺍﺠﻊ ﺍﻝﻌﺎﻝﻤﻴﺔ ﻓﻲ ﺤﺎل ﻭﺠﻭﺩﻫﺎ‬
‫ﻭﺫﻝﻙ ﻝﺘﺒﻴﻥ ﻁﺭﻕ ﺍﻝﺘﺨﺭﺏ ﺍﻝﻤﻘﺘﺭﺤﺔ‪.‬‬
‫‪ -‬ﻓﻲ ﺤﺎل ﻋﺩﻡ ﺘﻭﻓﺭ ﺒﻴﺎﻨﺎﺕ ﻓﻲ ﺍﻝﻤﺭﺍﺠﻊ ﺍﻝﻌﻠﻤﻴﺔ ﺒﻤﺎ ﻓﻲ ﺫﻝﻙ ﺩﺴﺎﺘﻴﺭ‬
‫ﺍﻷﺩﻭﻴﺔ ﻋﻨﺩﻫﺎ ﻴﺠﺏ ﺇﺠﺭﺍﺀ ﺩﺭﺍﺴﺎﺕ ﺜﺒﺎﺕ ﺘﺸﺩﺩﻴﺔ ‪ .‬ﺘﺸﻜل ﺍﻝﻤﻌﻠﻭﻤﺎﺕ‬
‫ﺍﻝﺘﻲ ﻴﺘﻡ ﺍﻝﺤﺼﻭل ﻋﻠﻴﻬﺎ ﻤﻥ ﺘﻠﻙ ﺍﻝﺩﺭﺍﺴﺎﺕ ﺍﻝﺠﺯﺀ ﺍﻝﺠﻭﻫﺭﻱ ﺍﻝﺫﻱ ﻴﻘﺩﻡ‬
‫ﻝﻠﺴﻠﻁﺎﺕ ﺍﻝﺼﺤﻴﺔ‪.‬‬
‫ﻤﻥ ﺍﻝﻤﺭﺠﺢ ﺃﻥ ﺘﺠﺭﻯ ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺜﺒﺎﺕ ﻝﻠﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﻋﻠﻰ ﺘﺤﻀﻴﺭﺓ ﻭﺍﺤﺩﺓ‪.‬‬
‫ﻴﺠﺏ ﺃﻥ ﺘﺘﻀﻤﻥ ﺘﺄﺜﻴﺭ ﺩﺭﺠﺎﺕ ﺍﻝﺤﺭﺍﺭﺓ ﺒﺸﻜل ﻤﺘﺩﺭﺝ ﻜل ‪ ١٠‬ﺩﺭﺠﺎﺕ )‬
‫ﻤﺜﺎل ‪... ٥٠،٦٠‬ﺍﻝﺦ( ﻭﺩﺭﺠﺎﺕ ﺤﺭﺍﺭﺓ ﺃﻋﻠﻰ ﻤﻥ ﺫﻝﻙ ﺒﺎﻝﻨﺴﺒﺔ ﻝﻠﺩﺭﺍﺴﺎﺕ‬
‫ﺍﻝﻤﺘﺸﺩﺩﺓ ﻭﺩﺭﺠﺔ ﺭﻁﻭﺒﺔ ﻨﺴﺒﻴﺔ )‪ %٧٥‬ﺃﻭ ﺃﻋﻠﻰ ﻤﻥ ﺫﻝﻙ ( ﻭﺘﻁﺒﻕ ﺒﺤﺴﺏ‬
‫ﺍﻝﻀﺭﻭﺭﺓ ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻷﻜﺴﺩﺓ ﻭﺍﻝﺘﺤﻠل ﺍﻝﻀﻭﺌﻲ ﻋﻠﻰ ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ‪ .‬ﻴﺠﺏ ﺃﻥ‬
‫ﺘﻘﻴﻡ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺃﻴﻀﺎ ﻝﻤﻼﺌﻤﺔ ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﻝﻺﻤﺎﻫﺔ ﺒﺩﺭﺠﺎﺕ ﺤﻤﻭﻀﺔ‬
‫ﻤﺨﺘﻠﻔﺔ ﻋﻨﺩﻤﺎ ﺘﻜﻭﻥ ﺍﻝﻤﺎﺩﺓ ﺒﺸﻜل ﻤﺤﻠﻭل ﺃﻭ ﻤﻌﻠﻕ ‪ .‬ﻴﺠﺏ ﺃﻥ ﺘﻜﻭﻥ‬
‫ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻀﻭﺌﻲ ﺠﺯﺀﺍ ﺃﺴﺎﺴﻴﺎ ﻤﻥ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺘﺸﺩﺩﻴﺔ ‪.‬‬
‫ﺇﻥ ﻓﺤﺹ ﻤﻭﺍﺩ ﺍﻝﺘﺨﺭﺏ ﻓﻲ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﺘﺸﺩﺩﻴﺔ ﻤﻔﻴﺩ ﻓﻲ ﺘﺤﺩﻴﺩ ﻁﺭﻕ‬
‫ﺍﻝﺘﺨﺭﺏ ﻭﺒﺎﻝﺘﺎﻝﻲ ﺘﻁﻭﻴﺭ ﻭﺍﻝﺘﺤﻘﻕ ﻤﻥ ﺼﻼﺤﻴﺔ ﺨﻁﻁ ﺍﻝﺘﺤﺎﻝﻴل‪ .‬ﻋﻠﻰ ﺃﻴﺔ‬
‫ﺤﺎل ﻝﻴﺱ ﻤﻥ ﺍﻝﻀﺭﻭﺭﻱ ﺍﻝﺒﺤﺙ ﻓﻲ ﻤﺸﺘﻘﺎﺕ ﺘﺨﺭﺏ ﻤﺤﺩﺩﺓ ﺇﺫﺍ ﺜﺒﺕ ﺃﻨﻬﺎ‬
‫ﻻﺘﺘﺸﻜل ﻓﻲ ﻅﺭﻭﻑ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺴﺭﻋﺔ ﺃﻭ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ‪.‬‬

‫‪ ٣,١,٢‬ﺇﺨﺘﻴﺎﺭ ﺍﻝﺘﺤﻀﻴﺭﺍﺕ ‪Selection of Batches‬‬


‫ﻴﻭﺠﺩ ﺇﺨﺘﻴﺎﺭﻴﻥ ﻤﻘﺒﻭﻝﻴﻥ‪:‬‬
‫ﺃ( ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﺒﻴﺎﻨﺎﺕ ﻭﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺴﺭﻋﺔ ﻭﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‬
‫ﻝﺘﺤﻀﻴﺭﺘﻴﻥ ﻴﺘﻡ ﺇﻨﺘﺎﺠﻬﻤﺎ ﺒﻁﺎﻗﺔ ﺇﻨﺘﺎﺠﻴﺔ ﻜﺎﻤﻠﺔ ﻝﻠﺨﻁ ﻭﺒﻨﻔﺱ ﻁﺭﻴﻘﺔ‬
‫ﺍﻝﺘﺼﻨﻴﻊ ﺍﻝﻤﻭﺼﻭﻓﺔ ﻓﻲ ﻤﻠﻑ ﺘﺴﺠﻴل ﺍﻝﺩﻭﺍﺀ ‪ ،‬ﻭﺃﻥ ﺘﻜﻭﻥ ﻤﺩﺓ ﻜل‬
‫ﺩﺭﺍﺴﺔ ﻻﺘﻘل ﻋﻥ ﺴﺘﺔ ﺃﺸﻬﺭ ‪.‬‬
‫ﺃﻭ‬
‫ﺏ( ﺘﻘﺩﻴﻡ ﺒﻴﺎﻨﺎﺕ ﻭﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺴﺭﻋﺔ ﻭﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻝﺜﻼﺙ‬
‫ﺘﺤﻀﻴﺭﺍﺕ ﺘﺠﺭﻴﺒﻴﺔ ﻴﺘﻡ ﺇﻨﺘﺎﺠﻬﻤﺎ ﺒﻁﺎﻗﺔ ﺇﻨﺘﺎﺠﻴﺔ ﻜﺎﻤﻠﺔ ﻝﻠﺨﻁ ﻭﺒﻨﻔﺱ‬
‫ﻁﺭﻴﻘﺔ ﺍﻝﺘﺼﻨﻴﻊ ﺍﻝﻤﻭﺼﻭﻓﺔ ﻓﻲ ﻤﻠﻑ ﺘﺴﺠﻴل ﺍﻝﺩﻭﺍﺀ ‪ ،‬ﻭﺃﻥ ﺘﻜﻭﻥ ﻤﺩﺓ‬
‫ﻜل ﺩﺭﺍﺴﺔ ﻻﺘﻘل ﻋﻥ ﺴﺘﺔ ﺃﺸﻬﺭ ‪.‬‬
‫‪ ٤,١,٢‬ﻨﻅﺎﻡ ﺍﻝﻌﺒﻭﺓ ﻭﺍﻹﻏﻼﻕ ‪Container Closure System‬‬

‫ﻴﺠﺏ ﺃﻥ ﺘﺠﺭﻯ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﻠﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﻓﻲ ﻨﻔﺱ ﻨﻅﺎﻡ ﺍﻝﻌﺒﻭﺓ‬


‫ﻭﺍﻹﻏﻼﻕ ﺍﻝﻤﺴﺘﺨﺩﻡ ﻓﻲ ﺍﻝﺘﺨﺯﻴﻥ ﻭﺍﻝﺘﻭﺯﻴﻊ ﺃﻭ ﺍﻝﺫﻱ ﻴﻤﺎﺜﻠﻪ ‪.‬‬

‫‪٥‬‬
‫‪ ٥,١,٢‬ﺍﻝﻤﻭﺍﺼﻔﺎﺕ ‪Specification‬‬

‫ﻴﺠﺏ ﺃﻥ ﺘﺘﻀﻤﻥ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﻠﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺘﻲ ﺘﻜﺸﻑ‬


‫ﺍﻝﺘﺒﺩﻻﺕ ﺨﻼل ﻓﺘﺭﺓ ﺍﻝﺘﺨﺯﻴﻥ ﻭﺍﻝﺘﻲ ﺘﺅﺜﺭ ﻓﻲ ﺍﻝﺠﻭﺩﺓ ﻭﺍﻝﻔﻌﺎﻝﻴﺔ ﻭﺍﻝﺴﻼﻤﺔ‬
‫‪.‬ﺍﻻﺨﺘﺒﺎﺭﺍﺕ ﻴﺠﺏ ﺃﻥ ﺘﺸﻤل ﺍﻝﻔﺤﻭﺹ ﺍﻝﻔﻴﺯﻴﺎﺌﻴﺔ ﻭﺍﻝﻜﻴﻤﻴﺎﺌﻴﺔ ﻭﺍﻝﺤﻴﻭﻴﺔ‬
‫ﻭﺍﻝﺠﺭﺜﻭﻤﻴﺔ ‪ .‬ﻜﻤﺎ ﺃﻨﻪ ﻴﺠﺏ ﺘﻁﺒﻴﻕ ﺨﻁﻁ ﺘﺤﻠﻴل ﻤﺅﺸﺭﺓ ﻝﻠﺜﺒﺎﺕ ﻗﺩ ﺘﻡ ﺍﻝﺘﺤﻘﻕ‬
‫ﻤﻥ ﺼﻼﺤﻴﺘﻬﺎ‪.‬‬
‫ﺍﻝﺤﺩﻭﺩ ﺍﻝﻤﻘﺒﻭﻝﺔ ﻫﻲ ﻗﻴﻡ ﺭﻗﻤﻴﺔ ﻤﺠﺎﻻﺕ ﻭﻤﻌﺎﻴﻴﺭ ﺃﺨﺭﻯ ﻝﻠﻔﺤﻭﺹ ﺍﻝﻨﻭﻋﻴﺔ‬
‫ﺍﻝﻤﺤﺩﺩﺓ ﻭﺃﻥ ﺘﺘﻀﻤﻥ ﺇﻓﺭﺍﺩﻴﺎ ﻭﻜﻠﻴﺎ ﺍﻝﺤﺩﻭﺩ ﺍﻝﻘﺼﻭﻯ ﻝﻠﺸﻭﺍﺌﺏ ﻭﻤﻭﺍﺩ ﺍﻝﺘﺨﺭﺏ‬
‫‪ .‬ﻴﺠﺏ ﺃﻥ ﻴﺴﺘﻨﺩ ﺍﻝﺘﺒﺭﻴﺭ ﺍﻝﻔﺭﺩﻱ ﻭﺍﻝﻜﻠﻲ ﻝﻠﺤﺩﻭﺩ ﺍﻝﻘﺼﻭﻯ ﻝﻤﻭﺍﺩ ﺍﻝﺘﺨﺭﺏ‬
‫ﻋﻠﻰ ﺇﻋﺘﺒﺎﺭﺍﺕ ﺍﻝﺴﻼﻤﺔ‪ /‬ﺍﻝﻔﻌﺎﻝﻴﺔ‪ .‬ﺒﺎﻝﻨﺴﺒﺔ ﻝﻠﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﺍﻝﻤﺫﻜﻭﺭﺓ ﻓﻲ ﺩﺴﺎﺘﻴﺭ‬
‫ﺍﻷﺩﻭﻴﺔ ﻓﺈﻥ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﻴﺠﺏ ﺃﻥ ﺘﺠﺭﻯ ﻭﻓﻘﺎ ﻝﻠﻨﺹ ﺍﻝﺩﺴﺘﻭﺭﻱ ﺃﻭ ﺒﺎﺴﺘﺨﺩﺍﻡ‬
‫ﺇﺨﺘﺒﺎﺭﺍﺕ ﺘﻡ ﺍﻝﺘﺤﻘﻕ ﻤﻥ ﺼﻼﺤﻴﺘﻬﺎ ﺒﺄﻜﺜﺭ ﻤﻥ ﻁﺭﻴﻘﺔ ﺒﺎﻝﻤﻘﺎﺭﻨﺔ ﻤﻊ ﺍﻝﻨﺹ‬
‫ﺍﻝﺩﺴﺘﻭﺭﻱ ﻭﺃﻥ ﺘﻘﺩﻡ ﺍﻝﺘﺒﺭﻴﺭﺍﺕ ﻴﺤﺩﺩ ﻓﻴﻬﺎ ﺒﺄﻥ ﺍﻝﺸﻭﺍﺌﺏ ﺍﻝﻤﺤﺘﻤﻠﺔ ) ﺍﻝﺸﻭﺍﺌﺏ‬
‫ﺃﺜﻨﺎﺀ ﺍﻝﺘﺤﻀﻴﺭ ﺃﻭ ﻤﻥ ﻤﺸﺘﻘﺎﺕ ﺍﻝﺘﺨﺭﺏ( ﻋﻨﻬﺎ ﻤﻥ ﺃﻥ ﺍﻝﺸﻭﺍﺌﺏ ﻫﻲ ﺘﻨﺠﻡ‬
‫ﺃﺜﻨﺎﺀ ﻋﻤﻠﻴﺔ ﺍﻝﺘﺨﻠﻴﻕ)ﺍﻝﺘﺼﻨﻴﻊ( ﺍﻝﻤﺘﺒﻌﺔ ﻭﺒﺄﻨﻬﺎ ﻤﺭﺍﻗﺒﺔ ﺒﺸﻜل ﻜﺎﻑ‪.‬‬

‫‪ ٦,١,٢‬ﺘﻜﺭﺍﺭﻴﺔ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ‪Testing Frequency‬‬

‫ﻓﻲ ﺤﺎﻝﺔ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻓﺈﻥ ﺘﻜﺭﺍﺭﻴﺔ ﺍﻝﻔﺤﻭﺹ ﻴﺠﺏ ﺃﻥ ﺘﻜﻭﻥ‬
‫ﻜﺎﻓﻴﺔ ﻝﺘﺤﻘﻴﻕ ﻤﻠﻑ ﺜﺒﺎﺕ ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ‪ .‬ﻓﻲ ﺤﺎﻝﺔ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ‬
‫ﺍﻷﻤﺩ ﻓﺈﻥ ﺘﻜﺭﺍﺭﻴﺔ ﺍﻝﻔﺤﻭﺹ ﻴﺠﺏ ﺃﻥ ﺘﺘﻡ ﻜل ﺜﻼﺜﺔ ﺃﺸﻬﺭ ﺨﻼل ﺍﻝﺴﻨﺔ‬
‫ﺍﻷﻭﻝﻰ ﻭﻜل ﺴﺘﺔ ﺃﺸﻬﺭ ﺨﻼل ﺍﻝﺴﻨﺔ ﺍﻝﺜﺎﻨﻴﺔ ﻭﺴﻨﻭﻴﺎ ﺒﻌﺩ ﺫﻝﻙ ﻭﻓﻘﺎ ﻝﺘﺎﺭﻴﺦ‬
‫ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﺍﻝﻤﻘﺘﺭﺤﺔ‪.‬‬
‫ﻓﻲ ﺤﺎﻝﺔ ﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺴﺭﻋﺔ ﻓﺈﻥ ﺍﻝﺤﺩﻭﺩ ﺍﻝﺩﻨﻴﺎ ﻝﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﻤﺩﺓ ﺴﺘﺔ‬
‫ﺃﺸﻬﺭﻫﻲ ﺜﻼﺙ ﻨﻘﺎﻁ‪ ،‬ﺘﺸﻤل ﺍﻝﺒﺩﺍﻴﺔ ﻭﺍﻝﻨﻬﺎﻴﺔ )ﻤﺜل ‪ ٠،٣،٦‬ﺃﺸﻬﺭ (‪.‬‬
‫ﻋﻨﺩ ﺇﻴﻘﺎﻑ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﻓﻲ ﻤﻨﺘﺼﻑ ﻓﺘﺭﺓ ﺍﻝﺘﺨﺯﻴﻥ ﺒﺴﺒﺏ ﺘﺒﺩﻻﺕ ﺸﺩﻴﺩﺓ ﻓﻲ‬
‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺴﺭﻋﺔ ﻋﻨﺩﻫﺎ ﻴﻁﻠﺏ ﺇﺠﺭﺍﺀ ﺃﺭﺒﻊ ﻨﻘﺎﻁ ﺇﺨﺘﺒﺎﺭ ﻜﺤﺩ ﺃﺩﻨﻰ‬
‫ﺒﺤﻴﺙ ﺘﺸﻤل ﺯﻤﻥ ﺍﻝﺒﺩﺍﻴﺔ ﻭﺍﻝﻨﻬﺎﻴﺔ )ﻤﺜل ‪ ٠،٣،٦،١٢‬ﺸﻬﺭ( ﻝﺩﺭﺍﺴﺔ ‪ ١٢‬ﺸﻬﺭ‬
‫ﻤﻘﺘﺭﺤﺔ‪.‬‬
‫ﻓﻲ ﺤﺎﻝﺔ ﺍﻷﺩﻭﻴﺔ ﺍﻝﻨﺒﺎﺘﻴﺔ ﺃﻭ ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺩﻭﺍﺌﻴﺔ ﺍﻝﻨﺒﺎﺘﻴﺔ ﺍﻝﺘﻲ ﻴﻘﺩﻡ ﺍﻝﻤﺼﻨﻊ‬
‫ﻝﻬﺎ ﺒﻴﺎﻨﺎﺕ ﺘﺎﺭﻴﺨﻴﺔ ﻝﻠﺘﺤﻀﻴﺭﺓ ﻓﺈﻨﻪ ﻴﻤﻜﻥ ﺘﺨﻔﻴﺽ ﺘﻜﺭﺍﺭﻴﺔ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﻝﻬﺎ‪.‬‬

‫‪٦‬‬
‫‪ ٧,١,٢‬ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ‪Storage Conditions‬‬

‫ﺒﺸﻜل ﻋﺎﻡ ‪ ،‬ﻴﺠﺏ ﺘﻘﻴﻴﻡ ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ )ﺘﺤﻤل ﻤﻨﺎﺴﺏ( ﺘﺨﺘﺒﺭ‬
‫ﺜﺒﺎﺘﻬﺎ ﺍﻝﺤﺭﺍﺭﻱ ﻭﻜﺫﻝﻙ ﺇﺫﺍ ﺍﻨﻁﺒﻕ ﻋﻠﻴﻬﺎ ﺫﻝﻙ ﺤﺴﺎﺴﻴﺘﻬﺎ ﻝﻠﺭﻁﻭﺒﺔ ‪ .‬ﻴﺠﺏ ﺃﻥ‬
‫ﺘﻜﻭﻥ ﻓﺘﺭﺓ ﺍﻝﺩﺭﺍﺴﺔ ﻭﺸﺭﻭﻁﻬﺎ ﻜﺎﻓﻴﺔ ﻝﺘﻐﻁﻲ ﺍﻝﺘﺨﺯﻴﻥ ﻭﺍﻝﺸﺤﻥ ﻭﺍﻹﺴﺘﻌﻤﺎل‬
‫ﺍﻝﻼﺤﻕ‪.‬‬
‫ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻝﻠﺨﻴﺎﺭﻴﻥ )ﺃ( ﻭ )ﺏ( ﻴﺠﺏ ﺃﻥ ﺘﻐﻁﻲ ﻤﺎ ﻻ ﻴﻘل‬
‫ﻋﻥ ﺴﺘﺔ ﺃﺸﻬﺭ ﻓﻲ ﻓﺘﺭﺓ ﺘﻘﺩﻴﻡ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﻜﻤﺎ ﻴﺠﺏ ﺃﻥ ﺘﺴﺘﻤﺭ ﻝﻤﺩﺓ ﻤﻥ‬
‫ﺍﻝﺯﻤﻥ ﺘﻜﻔﻲ ﻝﺘﻐﻁﻴﺔ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ‪ .‬ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﺒﻴﺎﻨﺎﺕ ﺇﻀﺎﻓﻴﺔ ﺘﻡ‬
‫ﺘﺠﻤﻴﻌﻬﺎ ﺨﻼل ﻓﺘﺭﺓ ﺍﻝﺘﻘﻴﻴﻡ ﻝﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﻓﻲ ﺤﺎل ﺘﻡ ﻁﻠﺒﻬﺎ ﻤﻥ ﺍﻝﺴﻠﻁﺎﺕ‬
‫ﺍﻝﺼﺤﻴﺔ ‪ .‬ﺒﻴﺎﻨﺎﺕ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺴﺭﻋﺔ ﻭﻤﻥ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺘﻭﺴﻁﺔ‬
‫ﻴﻤﻜﻥ ﺃﻥ ﺘﺴﺘﻌﻤل ﻝﺘﻘﻴﻴﻡ ﺘﺄﺜﻴﺭ ﺘﻌﺭﺽ ﺍﻝﻤﺎﺩﺓ ﻝﺸﺭﻭﻁ ﺘﺨﺘﻠﻑ ﻋﻥ ﺸﺭﻭﻁ‬
‫ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺼﺭﺡ ﺒﻬﺎ ﻓﻲ ﺍﻝﻌﻨﻭﻨﺔ ) ﻤﺜل ﺍﻝﺘﻲ ﺘﺤﺼل ﺨﻼل ﻓﺘﺭﺓ ﺍﻝﺸﺤﻥ(‪.‬‬

‫ﺇﻥ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺴﺭﻋﺔ ﻭﺍﻝﻤﺘﻭﺴﻁﺔ ﻭﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻝﻠﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﻴﺘﻡ‬
‫ﺫﻜﺭﻫﺎ ﺒﺎﻝﺘﻔﺼﻴل ﻓﻲ ﺍﻝﺒﻨﻭﺩ ﺍﻝﻤﺫﻜﻭﺭﺓ ﺃﺩﻨﺎﻩ‪ .‬ﺘﻁﺒﻕ ﺍﻝﺤﺎﻝﺔ ﺍﻝﻌﺎﻤﺔ ﺇﺫﺍ ﻝﻡ ﺘﻜﻥ‬
‫ﺍﻝﻔﺼﻭل ﺍﻝﻼﺤﻘﺔ ﺘﻐﻁﻲ ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ‪ .‬ﻴﻤﻜﻥ ﺍﺴﺘﺨﺩﺍﻡ ﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺨﺘﻠﻔﺔ‬
‫ﺇﺫﺍ ﺘﻡ ﺘﺒﺭﻴﺭ ﺫﻝﻙ‪.‬‬

‫‪ ١,٧,١,٢‬ﺤﺎﻝﺔ ﻋﺎﻤﺔ ‪General case‬‬

‫ﺍﻝﻔﺘﺭﺓ ﺍﻝﺯﻤﻨﻴﺔ ﺍﻝﺩﻨﻴﺎ‬ ‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ‬ ‫ﻨﻭﻉ ﺍﻝﺩﺭﺍﺴﺔ‬


‫ﺍﻝﺘﻲ ﺘﻐﻁﻴﻬﺎ ﺍﻝﺒﻴﺎﻨﺎﺕ ﻓﻲ‬
‫ﺯﻤﻥ ﺘﻘﺩﻴﻡ ﻤﻠﻑ‬
‫ﺍﻝﺘﺴﺠﻴل‬
‫‪ ٦ 25°C ± 2°C/60% RH ± 5% RH‬ﺸﻬﻭﺭ )ﺍﻝﺨﻴﺎﺭ ﺃ ﺃﻭ‬ ‫ﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‬
‫‪ or‬ﺏ(‬ ‫*‬
‫‪30°C ± 2°C/65% RH ± 5% RH‬‬
‫‪ ٦ 30°C ± 2°C/65% RH ± 5% RH‬ﺸﻬﻭﺭ‬ ‫ﻤﺘﻭﺴﻁﺔ**‬
‫‪ ٦ 40°C ± 2°C/75% RH ± 5% RH‬ﺸﻬﻭﺭ‬ ‫ﻤﺴﺭﻋﺔ**‬

‫*ﻋﻠﻰ ﻤﻘﺩﻡ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﺃﻥ ﻴﺤﺩﺩ ﻓﻴﻤﺎ ﺇﺫﺍ ﺘﻡ ﺇﺠﺭﺍﺀ ﺩﺭﺍﺴﺎﺕ ﺜﺒﺎﺕ ﻤﺴﺭﻋﺔ ﺒﺸﺭﻭﻁ ‪25°C‬‬
‫‪ ± 2°C/60% RH ± 5% RH‬ﺃﻭ ‪30°C ± 2°C/65% RH ± 5% RH‬‬

‫‪٧‬‬
‫** ﻓﻲ ﺤﺎﻝﺔ ﺍﻷﺩﻭﻴﺔ ﺍﻝﻨﺒﺎﺘﻴﺔ ﻭﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺩﻭﺍﺌﻴﺔ ﺍﻝﻨﺒﺎﺘﻴﺔ ‪ ،‬ﻓﺈﻨﻪ ﻴﻤﻜﻥ ﺤﺫﻑ ﺇﺨﺘﺒﺎﺭﺍﺕ‬
‫ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺨﺯﻨﺔ ﺒﺸﺭﻭﻁ ﻤﺴﺭﻋﺔ ﺃﻭ ﻤﺘﻭﺴﻁﺔ ﺇﺫﺍ ﺘﻡ ﺘﺒﺭﻴﺭﻫﺎ ﻤﻥ ﻗﺒل ﻤﻘﺩﻡ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﻓﻲ‬
‫ﺤﺎل ﺘﻡ ﻅﺭﻭﻑ ﺍﻝﺘﺨﺯﻴﻥ ﺃﻗل ﻤﻥ ‪ 25°C‬ﻭﺒﺄﻨﻪ ﻗﺩ ﺘﻡ ﻋﻨﻭﻨﺘﻬﺎ ﺒﺸﻜل ﻭﺍﻀﺢ ﻋﻠﻰ ﺍﻝﻤﻨﺘﺞ‪.‬‬

‫ﻋﻨﺩ ﺤﺩﻭﺙ ﺘﺒﺩﻻﺕ ﻤﻠﺤﻭﻅﺔ ﻓﻲ ﺃﻱ ﻭﻗﺕ ﺨﻼل ﻓﺘﺭﺓ ﺍﻝﺴﺘﺔ ﺃﺸﻬﺭ ﻓﻲ ﻨﺘﺎﺌﺞ ﻤﺭﺤﻠﺔ ﺸﺭﻭﻁ‬
‫ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺴﺭﻋﺔ ‪ ،‬ﻋﻨﺩﻫﺎ ﻴﻁﻠﺏ ﺇﺠﺭﺍﺀ ﺇﺨﺘﺒﺎﺭﺍﺕ ﺇﻀﺎﻓﻴﺔ ﻓﻲ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺘﻭﺴﻁﺔ‬
‫ﻭﺃﻥ ﺘﻘﻴﻡ ﺒﺎﻝﻤﻘﺎﺭﻨﺔ ﻤﻊ ﺍﻝﺘﺒﺩﻻﺕ ﺍﻝﻤﻠﺤﻭﻅﺔ ﺍﻝﻤﻘﺎﺴﺔ ﺴﺎﺒﻘﺎ‪ .‬ﻴﺠﺏ ﺃﻥ ﺘﺸﻤل ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﻓﻲ‬
‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺘﻭﺴﻁﺔ ﻜﺎﻓﺔ ﺍﻝﻔﺤﻭﺹ ‪ ،‬ﻤﺎ ﻝﻡ ﻴﺘﻡ ﺘﻘﺩﻴﻡ ﺃﺩﻝﺔ ﺘﺴﺘﺜﻨﻲ ﺫﻝﻙ‪ .‬ﺍﻝﻁﻠﺏ ﺍﻷﻭﻝﻲ‬
‫ﻴﺠﺏ ﺃﻥ ﻴﺸﻤل ﻨﺘﺎﺌﺞ ‪ ٦‬ﺃﺸﻬﺭ ﻋﻠﻰ ﺍﻷﻗل ﻤﻥ ﺃﺼل ﺩﺭﺍﺴﺔ ‪ ١٢‬ﺸﻬﺭ ﻓﻲ ﻅﺭﻭﻑ ﺘﺨﺯﻴﻥ‬
‫ﻤﺘﻭﺴﻁﺔ‪.‬‬

‫" ﺍﻝﺘﺒﺩﻻﺕ ﺍﻝﻤﻠﺤﻭﻅﺔ" ﺘﻌﺭﻑ ﺒﺎﻝﻨﺴﺒﺔ ﻝﻠﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﺒﺄﻨﻬﺎ ﺍﻝﻔﺸل ﻓﻲ ﻤﻁﺎﺒﻘﺔ ﺍﻝﻤﻭﺍﺼﻔﺎﺕ‪.‬‬

‫‪ ٢,٧,١,٢‬ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﺍﻝﺘﻲ ﻴﺠﺏ ﺃﻥ ﺘﺨﺯﻥ ﻓﻲ ﺍﻝﺒﺭﺍﺩ‬


‫‪Active substances intended for storage in a refrigerator‬‬

‫ﺍﻝﻔﺘﺭﺓ ﺍﻝﺯﻤﻨﻴﺔ ﺍﻝﺩﻨﻴﺎ ﺍﻝﺘﻲ‬ ‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ‬ ‫ﻨﻭﻉ ﺍﻝﺩﺭﺍﺴﺔ‬


‫ﺘﻐﻁﻴﻬﺎ ﺍﻝﺒﻴﺎﻨﺎﺕ ﻓﻲ ﺯﻤﻥ‬
‫ﺘﻘﺩﻴﻡ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل‬
‫‪ ٦‬ﺸﻬﻭﺭ )ﺍﻝﺨﻴﺎﺭ ﺃ ﺃﻭ ﺏ(‬ ‫‪5°C ± 3°C‬‬ ‫ﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‬
‫‪ ٦ 25°C ± 2°C/60% RH ± 5% RH‬ﺸﻬﻭﺭ‬ ‫ﻤﺴﺭﻋﺔ‬

‫ﻴﺠﺏ ﺘﻘﻴﻴﻡ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺘﺨﺯﻴﻥ ﻓﻲ ﺍﻝﺒﺭﺍﺩ ﺘﺒﻌﺎ ﻝﻠﻘﺴﻡ ﺍﻝﻤﺘﻌﻠﻕ ﺒﺘﻘﻴﻴﻡ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ‬
‫ﺍﻝﻤﺫﻜﻭﺭﺓ ﻓﻲ ﻫﺫﺍ ﺍﻝﺩﻝﻴل‪ ،‬ﺒﺎﺴﺘﺜﻨﺎﺀ ﺍﻝﺫﻱ ﺴﻴﺘﻡ ﺫﻜﺭﻩ ﺃﺩﻨﺎﻩ ﺒﻜل ﻭﻀﻭﺡ ﻭﺼﺭﺍﺤﺔ‪.‬‬

‫ﺇﺫﺍ ﺤﺼل ﺘﺒﺩل ﻤﻠﺤﻭﻅ ﺒﻴﻥ ‪ ٣‬ﻭ‪ ٦‬ﺸﻬﻭﺭ ﻓﻲ ﺍﻝﺩﺭﺍﺴﺔ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺴﺭﻋﺔ ‪ ،‬ﻓﺈﻥ ﺘﺎﺭﻴﺦ‬
‫ﺇﻋﺎﺩﺓ ﺍﻝﻔﺤﺹ ﻴﺠﺏ ﺃﻥ ﻴﺴﺘﻨﺩ ﻋﻠﻰ ﻨﺘﺎﺌﺞ ﺍﻝﺯﻤﻥ ﺍﻝﺤﻘﻴﻘﻲ ﺍﻝﻤﺘﻭﻓﺭﺓ ﻓﻲ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ‬
‫ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‪.‬‬

‫ﺇﺫﺍ ﺤﺼل ﺘﺒﺩل ﻤﻠﺤﻭﻅ ﺨﻼل ﺍﻝﺜﻼﺜﺔ ﺃﺸﻬﺭ ﺍﻷﻭﻝﻰ ﻓﻲ ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺨﺯﻨﺔ ﺒﺸﺭﻭﻁ‬
‫ﻤﺴﺭﻋﺔ ‪ ،‬ﻓﺈﻥ ﺍﻝﻨﻘﺎﺵ ﻴﺠﺏ ﺃﻥ ﻴﻘﺩﻡ ﺩﻻﺌل ﺘﺸﻴﺭ ﺇﻝﻰ ﺍﻝﺘﺄﺜﻴﺭﺍﺕ ﺍﻝﺘﻲ ﺘﺤﺼل ﻋﻨﺩ ﺘﻌﺭﻴﺽ‬
‫ﺍﻝﻤﺴﺘﺤﻀﺭ ﻝﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﺘﺨﺘﻠﻑ ﻋﻥ ﺍﻝﻤﻨﺼﻭﺹ ﻋﻠﻴﻬﺎ ﻓﻲ ﺍﻝﻌﻨﻭﻨﺔ‪ .‬ﻤﺜﺎل ﻋﻨﺩ ﺸﺤﻥ ﺍﻝﻤﺎﺩﺓ‬
‫ﺃﻭ ﺍﻝﺘﻌﺎﻭل ﻤﻌﻬﺎ‪ .‬ﻫﺫﺍ ﺍﻝﻨﻘﺎﺵ ﻴﻤﻜﻥ ﺃﻥ ﻴﺩﻋﻡ ‪ ،‬ﺇﺫﺍ ﻜﺎﻥ ﻤﻨﺎﺴﺒﺎ‪ ،‬ﻤﻥ ﺨﻼل ﺇﺨﺘﺒﺎﺭﺍﺕ ﺇﻀﺎﻓﻴﺔ‬
‫ﺘﺠﺭﻯ ﻋﻠﻰ ﺘﺤﻀﻴﺭﺓ ﻭﺍﺤﺩﺓ ﻝﻠﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﻝﻤﺩﺓ ﺘﻘل ﻋﻥ ﺜﻼﺜﺔ ﺃﺸﻬﺭ ﻝﻜﻥ ﺒﺘﻜﺭﺍﺭﻴﺔ ﺃﻜﺜﺭ‬

‫‪٨‬‬
‫ﻝﻺﺨﺘﺒﺎﺭﺍﺕ ﻋﻥ ﺍﻝﺫﻱ ﻴﺘﻡ ﻋﺎﺩﺓ‪ .‬ﻴﻌﺘﺒﺭ ﻏﻴﺭ ﻀﺭﻭﺭﻱ ﺍﻻﺴﺘﻤﺭﺍﺭ ﻓﻲ ﺩﺭﺍﺴﺔ ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ‬
‫ﺨﻼل ﺴﺘﺔ ﺃﺸﻬﺭ ﺇﺫﺍ ﺤﺼل ﺘﺒﺩﻻﺕ ﻤﻠﺤﻭﻅﺔ ﺨﻼل ﺍﻝﺜﻼﺜﺔ ﺃﺸﻬﺭ ﺍﻷﻭﻝﻰ‪.‬‬

‫‪ ٣,٧,١,٢‬ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﺍﻝﺘﻲ ﺘﺨﺯﻥ ﻓﻲ ﺍﻝﻤﺠﻤﺩﺓ‬


‫‪Active substances intended for storage in a freezer‬‬

‫ﺍﻝﻔﺘﺭﺓ ﺍﻝﺯﻤﻨﻴﺔ ﺍﻝﺩﻨﻴﺎ ﺍﻝﺘﻲ‬ ‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ‬ ‫ﻨﻭﻉ ﺍﻝﺩﺭﺍﺴﺔ‬


‫ﺘﻐﻁﻴﻬﺎ ﺍﻝﺒﻴﺎﻨﺎﺕ ﻓﻲ ﺯﻤﻥ‬
‫ﺘﻘﺩﻴﻡ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل‬
‫‪ ٦‬ﺸﻬﻭﺭ )ﺍﻝﺨﻴﺎﺭ ﺃ ﺃﻭ ﺏ(‬ ‫‪-20°C ± 5°C‬‬ ‫ﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‬

‫ﺒﺎﻝﻨﺴﺒﺔ ﻝﻠﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﺍﻝﺘﻲ ﻴﻌﺩ ﻝﻬﺎ ﺍﻝﺘﺨﺯﻴﻥ ﻓﻲ ﺍﻝﻤﺠﻤﺩﺓ ‪ ،‬ﻓﺈﻥ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﻴﺠﺏ ﺃﻥ‬
‫ﺘﻌﺘﻤﺩ ﻋﻠﻰ ﻨﺘﺎﺌﺞ ﺒﻴﺎﻨﺎﺕ ﺍﻝﺯﻤﻥ ﺍﻝﺤﻘﻴﻘﻲ ﺍﻝﺘﻲ ﻴﺘﻡ ﺍﻝﺤﺼﻭل ﻋﻠﻴﻬﺎ ﻤﻥ ﺍﻝﺩﺭﺍﺴﺔ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ‬
‫ﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‪ .‬ﻓﻲ ﻏﻴﺎﺏ ﺍﻝﺩﺭﺍﺴﺔ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺴﺭﻋﺔ ﻝﻠﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﻭﺍﻝﺘﻲ ﻴﻌﺩ ﻝﻬﺎ ﺃﻥ‬
‫ﺘﺨﺯﻥ ﻓﻲ ﺍﻝﻤﺠﻤﺩﺓ ‪ ،‬ﻓﺈﻥ ﺍﻝﻔﺤﻭﺹ ﻴﺠﺏ ﺃﻥ ﺘﺠﺭﻯ ﻋﻠﻰ ﺘﺤﻀﻴﺭﺓ ﻭﺍﺤﺩﺓ ﺒﺩﺭﺠﺎﺕ ﺤﺭﺍﺭﺓ‬
‫ﻤﺭﺘﻔﻌﺔ ) ﻤﺜل ‪ 5°C ± 3°C‬ﺃﻭ ‪ ( 25°C ± 2°C‬ﻭﺫﻝﻙ ﻝﻔﺘﺭﺓ ﺯﻤﻨﻴﺔ ﻤﻨﺎﺴﺒﺔ ‪ .‬ﻤﺜل ﻫﺫﻩ‬
‫ﺍﻝﺩﺭﺍﺴﺔ ﺘﻘﺩﻡ ﺒﻴﺎﻨﺎﺕ ﺤﻭل ﺘﺄﺜﻴﺭ ﺘﻌﺭﺽ ﺍﻝﻤﺎﺩﺓ ﻝﻔﺘﺭﺓ ﻗﺼﻴﺭﺓ ﻝﻅﺭﻭﻑ ﺍﻝﻨﻘل ﻭﺍﻝﺸﺤﻥ ﻭﺍﻝﺘﻌﺎﻤل‬
‫ﻤﻊ ﺍﻝﻤﺎﺩﺓ ﺘﺨﺘﻠﻑ ﻋﻥ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺼﺭﺡ ﻋﻨﻬﺎ ﻓﻲ ﺍﻝﻌﻨﻭﻨﺔ‪.‬‬

‫‪ ٤,٧,١,٢‬ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﺍﻝﻤﻌﺩﺓ ﻝﻠﺘﺨﺯﻴﻥ ﺒﺸﺭﻭﻁ ﺃﻗل ﻤﻥ ‪-20°C‬‬


‫‪Active substances intended for storage below -20°C‬‬

‫ﻴﺠﺏ ﻤﻌﺎﻤﻠﺔ ﺍﻝﻤﻭﺍﺩ ﺍﻷﻭﻝﻴﺔ ﺍﻝﻔﻌﺎﻝﻴﺔ ﺍﻝﻤﻌﺩﺓ ﻝﻠﺘﺨﺯﻴﻥ ﺒﺸﺭﻭﻁ ﺃل ﻤﻥ ‪ -20°C‬ﺒﺤﺴﺏ ﻜل ﺤﺎﻝﺔ‪.‬‬

‫‪ ٨,١,٢‬ﺘﻌﻬﺩ ﺍﻝﺜﺒﺎﺕ ‪Stability commitment‬‬

‫ﻋﻨﺩﻤﺎ ﺘﻜﻭﻥ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻝﻠﺘﺤﻀﻴﺭﺍﺕ ﺍﻷﻭﻝﻴﺔ ﻻﺘﻐﻁﻲ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ‬
‫ﺍﻹﺨﺘﺒﺎﺭ ﺍﻝﻤﻘﺘﺭﺤﺔ ﻭﺍﻝﺘﻲ ﺘﻡ ﺍﻝﻤﻭﺍﻓﻘﺔ ﻋﻠﻴﻬﺎ ﺨﻼل ﻓﺘﺭﺓ ﺍﻝﺘﻘﻴﻴﻡ ﻝﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﻋﻨﺩﻫﺎ ﻴﺠﺏ‬
‫ﺘﻘﺩﻴﻡ ﺘﻌﻬﺩ ﻝﻺﺴﺘﻤﺭﺍﺭ ﺒﺈﺠﺭﺍﺀ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺒﻌﺩ ﻤﻨﺢ ﺍﻝﺘﺭﺨﻴﺹ ﺍﻝﻼﺯﻡ ﻤﻥ ﺃﺠل ﺘﺤﻘﻴﻕ‬
‫ﻭﺒﺸﻜل ﻤﺅﻜﺩ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ‪.‬‬

‫‪٩‬‬
‫ﻋﻨﺩ ﺘﻘﺩﻴﻡ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻝﺜﻼﺙ ﺘﺤﻀﻴﺭﺍﺕ ﺼﻨﺎﻋﻴﺔ ﻴﺘﻡ ﻓﻴﻬﺎ ﺘﻐﻁﻴﺔ ﻤﺩﺓ‬
‫ﺍﻹﺨﺘﺒﺎﺭ ‪ ،‬ﻋﻨﺩﻫﺎ ﻝﻴﺱ ﻤﻥ ﺍﻝﻀﺭﻭﺭﻱ ﺘﻘﺩﻴﻡ ﺘﻌﻬﺩ ﺍﻝﺜﺒﺎﺕ ﺒﻌﺩ ﻤﻨﺢ ﺍﻝﺘﺭﺨﻴﺹ ﺍﻝﻼﺯﻡ ‪ .‬ﺨﻼﻑ‬
‫ﺫﻝﻙ ﻓﺈﻨﻪ ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﺃﺤﺩ ﺍﻝﺘﻌﻬﺩﺍﺕ ﺍﻝﺘﺎﻝﻴﺔ‪:‬‬
‫‪ .١‬ﺇﺫﺍ ﻜﺎﻥ ﺍﻝﻤﻠﻑ ﺍﻝﻤﻘﺩﻡ ﻝﻠﺘﺴﺠﻴل ﻴﺘﻀﻤﻥ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﺜﻼﺙ ﺘﺤﻀﻴﺭﺍﺕ‬
‫ﺼﻨﺎﻋﻴﺔ ﻋﻠﻰ ﺍﻷﻗل ‪ ،‬ﻋﻨﺩﻫﺎ ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﺘﻌﻬﺩ ﻝﻺﺴﺘﻤﺭﺍﺭ ﺒﺘﻠﻙ ﺍﻝﺩﺭﺍﺴﺎﺕ‬
‫ﻝﻠﻭﺼﻭل ﻝﻔﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ‪.‬‬
‫‪ .٢‬ﺇﺫﺍ ﻜﺎﻥ ﺍﻝﻤﻠﻑ ﺍﻝﻤﻘﺩﻡ ﻝﻠﺘﺴﺠﻴل ﻴﺘﻀﻤﻥ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺜﺒﺎﺕ ﺃﻗل ﻤﻥ ﺜﻼﺙ‬
‫ﺘﺤﻀﻴﺭﺍﺕ ﺼﻨﺎﻋﻴﺔ ‪ ،‬ﻋﻨﺩﻫﺎ ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﺘﻌﻬﺩ ﻝﻺﺴﺘﻤﺭﺍﺭ ﺒﺘﻠﻙ ﺍﻝﺩﺭﺍﺴﺎﺕ‬
‫ﻝﻠﻭﺼﻭل ﻝﻔﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﻭﺇﻀﺎﻓﺔ ﺘﺤﻀﻴﺭﺍﺕ ﺼﻨﺎﻋﻴﺔ ﻝﻠﻭﺼﻭل ﻝﻤﺠﻤﻭﻉ‬
‫ﺜﻼﺙ ﺘﺤﻀﻴﺭﺍﺕ ﻭﺃﻥ ﺘﺠﺭﻯ ﻋﻠﻴﻬﺎ ﺩﺭﺍﺴﺎﺕ ﺜﺒﺎﺕ ﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻝﻠﻭﺼﻭل ﺇﻝﻰ‬
‫ﺘﺎﺭﻴﺦ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﺍﻝﻤﻘﺘﺭﺤﺔ ﻓﻲ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل‪.‬‬
‫‪ .٣‬ﺇﺫﺍ ﻜﺎﻥ ﺍﻝﻤﻠﻑ ﺍﻝﻤﻘﺩﻡ ﻝﻠﺘﺴﺠﻴل ﻻ ﻴﺘﻀﻤﻥ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﺜﻼﺙ‬
‫ﺘﺤﻀﻴﺭﺍﺕ ﺼﻨﺎﻋﻴﺔ ‪ ،‬ﻋﻨﺩﻫﺎ ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﺘﻌﻬﺩ ﻝﻺﺴﺘﻤﺭﺍﺭ ﺒﺘﻠﻙ ﺍﻝﺩﺭﺍﺴﺎﺕ ﻝﺜﻼﺙ‬
‫ﺘﺤﻀﻴﺭﺍﺕ ﺼﻨﺎﻋﻴﺔ ﻭﺃﻥ ﺘﺠﺭﻯ ﻋﻠﻴﻬﺎ ﺩﺭﺍﺴﺎﺕ ﺜﺒﺎﺕ ﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻝﻠﻭﺼﻭل ﺇﻝﻰ‬
‫ﺘﺎﺭﻴﺦ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﺍﻝﻤﻘﺘﺭﺤﺔ ﻓﻲ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل‪.‬‬

‫ﻴﺠﺏ ﺃﻥ ﻴﻜﻭﻥ ﺒﺭﻭﺘﻭﻜﻭل ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺘﺒﻊ ﻓﻲ ﺘﻌﻬﺩ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻫﻭ ﻨﻔﺴﻪ‬
‫ﺍﻝﻤﺴﺘﻌﻤل ﻝﻠﺘﺤﻀﻴﺭﺍﺕ ﺍﻝﺘﺠﺭﻴﺒﻴﺔ ﺍﻷﻭﻝﻴﺔ ‪ ،‬ﻤﺎ ﻋﺩﺍ ﺒﻌﺽ ﺍﻝﺤﺎﻻﺕ ﺍﻝﺘﻲ ﻴﻤﻜﻥ ﺘﺒﺭﻴﺭﻫﺎ ﻋﻠﻤﻴﺎ‪.‬‬

‫‪ ٩,١,٢‬ﺍﻝﺘﻘﻴﻴﻡ ‪Evaluation‬‬

‫ﺇﻥ ﺍﻝﻬﺩﻑ ﻤﻥ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻫﻭ ﻝﻠﺘﺄﻜﺩ ‪ ،‬ﺒﺎﻻﻋﺘﻤﺎﺩ ﻋﻠﻰ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺘﻲ ﺘﺠﺭﻯ ﻋﻠﻰ ﺍﻷﻗل‬
‫ﻝﺘﺤﻀﻴﺭﺘﻴﻥ ﺃﻭ ﺜﻼﺙ ﺘﺤﻀﻴﺭﺍﺕ ﻤﻥ ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﻭﺘﻘﻴﻴﻡ ﻤﻌﻠﻭﻤﺎﺕ ﺍﻝﺜﺒﺎﺕ ) ﺘﺘﻀﻤﻥ ﺒﺤﺴﺏ‬
‫ﺍﻝﻀﺭﻭﺭﺓ ﻨﺘﺎﺌﺞ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﻔﻴﺯﻴﺎﺌﻴﺔ ﻭﺍﻝﻜﻴﻤﻴﺎﺌﻴﺔ ﻭﺍﻝﺤﻴﻭﻴﺔ ﻭﺍﻝﺠﺭﺜﻭﻤﻴﺔ ( ‪ ،‬ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ‬
‫ﺍﻹﺨﺘﺒﺎﺭ ﺘﻨﻁﺒﻕ ﻋﻠﻰ ﺠﻤﻴﻊ ﺍﻝﺘﺤﻀﻴﺭﺍﺕ ﺍﻝﺘﻲ ﺴﻴﺘﻡ ﺘﺼﻨﻴﻌﻬﺎ ﻤﺴﺘﻘﺒﻼ ﺒﺎﺘﺒﺎﻉ ﻨﻔﺱ ﻁﺭﻴﻘﺔ‬
‫ﺍﻝﺘﺼﻨﻴﻊ ﻝﻠﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﻭﺘﺤﺕ ﺸﺭﻭﻁ ﻤﻤﺎﺜﻠﺔ ‪.‬ﺇﻥ ﺩﺭﺠﺔ ﺍﻝﺘﺒﺎﻴﻥ ﻭﺍﻹﺨﺘﻼﻑ ﻓﻲ ﺍﻝﺘﺤﻀﻴﺭﺍﺕ‬
‫ﺍﻝﻔﺭﺩﻴﺔ ﻴﺅﺜﺭ ﻓﻲ ﺍﻝﺜﻘﺔ ﺒﺄﻥ ﺍﻝﺘﺤﻀﻴﺭﺍﺕ ﺍﻝﺘﻲ ﺴﻴﺘﻡ ﺇﻨﺘﺎﺠﻬﺎ ﻤﺴﺘﻘﺒﻼ ﺴﺘﺒﻘﻰ ﻀﻤﻥ ﺍﻝﻤﻭﺍﺼﻔﺎﺕ‬
‫ﻁﻴﻠﺔ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ‪.‬‬
‫ﻴﻤﻜﻥ ﺃﻥ ﺘﻅﻬﺭ ﺍﻝﺒﻴﺎﻨﺎﺕ ﺘﺨﺭﺏ ﻗﻠﻴل ﻭﺍﺨﺘﻼﻑ ﻗﻠﻴل ﺠﺩﺍ ﻴﻤﻜﻥ ﻤﻼﺤﻅﺘﻪ ﻋﻨﺩ ﺍﻝﻨﻅﺭ ﻓﻲ ﻨﺘﺎﺌﺞ‬
‫ﺍﻝﺩﺭﺍﺴﺔ ﺒﺤﻴﺙ ﻴﺘﻡ ﻤﻨﺢ ﺍﻝﻤﻭﺍﻓﻘﺔ ﻋﻠﻰ ﺘﺎﺭﻴﺦ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﺍﻝﻤﻁﻠﻭﺏ ‪ .‬ﻓﻲ ﻤﺜل ﺘﻠﻙ ﺍﻝﺤﺎﻻﺕ‬
‫‪ ،‬ﻓﺈﻨﻪ ﻤﻥ ﻏﻴﺭ ﺍﻝﻀﺭﻭﺭﻱ ﻹﺠﺭﺍﺀ ﺘﺤﻠﻴل ﺇﺤﺼﺎﺌﻲ ؛ﺇﺫﺍ ﺜﺒﺕ ﺒﺄﻥ ﺍﻝﺤﺫﻑ ﻤﻘﻨﻌﺎ ‪.‬‬
‫ﺇﻥ ﺍﻝﻤﻨﺤﻰ ﻝﺘﺤﻠﻴل ﺍﻝﻨﺘﺎﺌﺞ ﺒﺸﻜل ﻜﻤﻲ ﻝﻠﻤﻭﺍﺩ ﺍﻝﺘﻲ ﻴﻤﻜﻥ ﺃﻥ ﺘﺘﺒﺩل ﻤﻊ ﺍﻝﺯﻤﻥ ﻭﺫﻝﻙ ﻝﺘﺤﺩﻴﺩ‬
‫ﺍﻝﺯﻤﻥ ﺍﻝﺘﻲ ﺘﺸﻜل ﻓﻴﻪ ﺍﻝﺜﻘﺔ ﻓﻲ ﺍﻝﻨﺘﺎﺌﺞ ﺒﺎﺘﺠﺎﻩ ﻭﺍﺤﺩ ﻨﺴﺒﺘﺔ ‪ %٩٥‬ﻭﺒﺄﻥ ﺍﻝﻤﻨﺤﻨﻰ ﺍﻝﻭﺴﻁﻲ‬
‫ﻴﺘﻘﺎﻁﻊ ﻤﻊ ﻤﺘﻁﻠﺒﺎﺕ ﺍﻝﻘﺒﻭل ﺍﻝﻘﻴﺎﺴﻲ‪ .‬ﺇﺫﺍ ﺒﻴﻨﺕ ﺍﻝﻨﺘﺎﺌﺞ ﺒﺄﻥ ﺍﻹﺨﺘﻼﻓﺎﺕ ﻤﻥ ﺘﺤﻀﻴﺭﺓ ﻝﺘﺤﻀﻴﺭﺓ‬
‫ﺼﻐﻴﺭ ﻋﻨﺩﻫﺎ ﻴﻜﻭﻥ ﻤﻥ ﺍﻝﻤﻔﻀل ﺠﻤﻊ ﺍﻝﺒﻴﺎﻨﺎﺕ ﻝﻠﻭﺼﻭل ﻝﺘﻘﺩﻴﺭ ﺇﺠﻤﺎﻝﻲ‪ .‬ﻴﻤﻜﻥ ﺘﺤﻘﻴﻕ ﺫﻝﻙ‬

‫‪١٠‬‬
‫ﻤﻥ ﺨﻼل ﺘﻁﺒﻴﻕ ﺇﺨﺘﺒﺎﺭﺍﺕ ﺇﺤﺼﺎﺌﻴﺔ ﻤﻨﺎﺴﺒﺔ )ﻤﺜل ‪ ،.‬ﺤﺩﻭﺩ ﻗﻴﻡ ﺍﻝﺭﻓﺽ ﺫﻭ ﺍﻷﻫﻤﻴﺔ ﺇﺫﺍ ﻜﺎﻨﺕ‬
‫ﺃﻜﺜﺭ ﻤﻥ ‪.( ٠,٢٥‬‬
‫ﺇﻥ ﺃﻱ ﺘﻘﻴﻴﻡ ﻴﺠﺏ ﺃﻥ ﻴﻐﻁﻲ ﻝﻴﺱ ﻓﻘﻁ ﺍﻝﻤﻌﺎﻴﺭﺓ ‪ ،‬ﺒل ﻴﺠﺏ ﺃﻥ ﻴﻐﻁﻲ ﺃﻴﻀﺎ ﻤﻭﺍﺩ ﺍﻝﺘﺨﺭﺏ‬
‫ﻭﺍﻝﻌﻭﺍﻤل ﺍﻝﻤﺸﺎﺭﻜﺔ ﺍﻷﺨﺭﻯ ‪.‬‬

‫‪ ١٠,١,٢‬ﺘﺼﺭﻴﺢ‪ /‬ﺍﻝﻌﻨﻭﻨﺔ ‪Statements/Labelling‬‬

‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ )ﺤﺭﺍﺭﺓ ‪ ،‬ﻀﻭﺀ ‪ ،‬ﺭﻁﻭﺒﺔ( ﺍﻝﻤﺼﺭﺡ ﺒﻬﺎ ﻴﺠﺏ ﺃﻥ ﺘﺴﺘﻨﺩ ﻋﻠﻰ ﺩﻝﻴل ﺘﺼﺭﻴﺢ‬
‫ﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺩﻭﺍﺌﻴﺔ – ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ‪.‬‬
‫ﺇﻥ ﺍﺴﺘﻌﻤﺎل ﺘﻌﺎﺒﻴﺭ ﻤﺜل ﺍﻝﺸﺭﻭﻁ ﺍﻝﻁﺒﻴﻌﻴﺔ ﺃﻭ ﺤﺭﺍﺭﺓ ﺍﻝﻐﺭﻓﺔ ﻫﻭ ﻏﻴﺭ ﻤﻘﺒﻭل‪.‬‬

‫‪١١‬‬
‫‪ ٢,٢‬ﺍﻝﻤﺴﺘﺤﻀﺭ ﺍﻝﺠﺎﻫﺯ ‪Finished product‬‬
‫‪ ١,٢,٢‬ﻋﺎﻡ ‪General‬‬

‫ﺇﻥ ﺘﺼﻤﻴﻡ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﻠﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺠﺎﻫﺯﺓ ﻴﻤﻜﻥ ﺃﻥ ﻴﺴﺘﻨﺩ ﺇﻝﻰ ﺍﻝﻤﻌﺭﻓﺔ ﻓﻲ ﺨﻭﺍﺹ‬
‫ﻭﺴﻠﻭﻙ ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﻭﺍﻝﺸﻜل ﺍﻝﺼﻴﺩﻻﻨﻲ ‪.‬‬

‫‪ ٢,٢,٢‬ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻀﻭﺌﻲ ‪Photostability Testing‬‬

‫ﻴﺠﺏ ﺇﺠﺭﺍﺀ ﺇﺨﺘﺒﺎﺭ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻀﻭﺌﻲ ﻋﻠﻰ ﺘﺤﻀﻴﺭﺓ ﺘﺠﺭﻴﺒﻴﺔ ﻭﺍﺤﺩﺓ ﻝﻠﻤﺴﺘﺤﻀﺭﺍﻝﺠﺎﻫﺯ ﻋﻠﻰ‬
‫ﺍﻷﻗل ﺇﺫﺍ ﻜﺎﻥ ﺫﻝﻙ ﻤﻼﺌﻤﺎ‪.‬‬

‫‪ ٣,٢,٢‬ﺇﺨﺘﻴﺎﺭ ﺍﻝﺘﺤﻀﻴﺭﺍﺕ ‪Selection of Batches‬‬

‫ﻓﻲ ﺍﻝﻭﻗﺕ ﺍﻝﺫﻱ ﻴﺘﻡ ﻓﻴﻪ ﺘﻘﺩﻴﻡ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻓﺈﻨﻬﺎ ﻴﺠﺏ ﺃﻥ ﺘﻜﻭﻥ ﻝﺘﺤﻀﻴﺭﺍﺕ ﺒﻨﻔﺱ‬
‫ﺍﻝﺘﺭﻜﻴﺏ ﻭﺍﻝﺸﻜل ﺍﻝﺼﻴﺩﻻﻨﻲ ﻭﻨﻅﺎﻡ ﺍﻝﺘﻌﺒﺌﺔ ﻭﺍﻝﺘﻐﻠﻴﻑ ﻝﻠﻤﺴﺘﺤﻀﺭ ﺍﻝﺫﻱ ﺴﻴﻁﺭﺡ ﻓﻲ ﺍﻷﺴﻭﺍﻕ‪.‬‬
‫ﻴﻭﺠﺩ ﺇﺨﺘﻴﺎﺭﻴﻥ ﻤﻘﺒﻭﻝﻴﻥ‪:‬‬
‫ﺃ( ﻓﻲ ﺤﺎﻝﺔ ﺍﻷﺸﻜﺎل ﺍﻝﺼﻴﺩﻻﻨﻴﺔ ﺍﻝﺘﻘﻠﻴﺩﻴﺔ )ﻤﺜل‪ ،‬ﺍﻷﺸﻜﺎل ﺍﻝﺼﻴﺩﻻﻨﻴﺔ‬
‫ﺍﻝﻔﻭﺭﻴﺔ ﺍﻝﺘﺤﺭﻴﺭ‪ ،‬ﺍﻝﻤﺤﺎﻝﻴل( ﻭﺇﺫﺍ ﻜﺎﻨﺕ ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﻤﻌﺭﻭﻓﺔ ﺒﺄﻨﻬﺎ ﺜﺎﺒﺘﺔ‬
‫‪ ،‬ﻓﺈﻨﻪ ﻴﻤﻜﻥ ﻗﺒﻭل ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﺘﺤﻀﻴﺭﺘﻴﻥ ﺘﺠﺭﻴﺒﻴﺘﻴﻥ‪.‬‬

‫ﺏ( ﻓﻲ ﺤﺎﻝﺔ ﺍﻷﺸﻜﺎل ﺍﻝﺼﻴﺩﻻﻨﻴﺔ ﺍﻝﺤﺭﺠﺔ ﺃﻭ ﻓﻲ ﺤﺎﻝﺔ ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ‬


‫ﺍﻝﻤﻌﺭﻭﻑ ﺒﺄﻨﻬﺎ ﻏﻴﺭ ﺜﺎﺒﺘﺔ ‪ ،‬ﻋﻨﺩﻫﺎ ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ‬
‫ﻝﺘﺤﻀﻴﺭﺘﻴﻥ ﺘﺠﺭﻴﺒﻴﺘﻴﻥ ﻭﺍﻝﺘﺤﻀﻴﺭﺓ ﺍﻝﺜﺎﻝﺜﺔ ﻴﻤﻜﻥ ﺃﻥ ﺘﻜﻭﻥ ﺃﺼﻐﺭ‪.‬‬

‫ﻴﺠﺏ ﺃﻥ ﺘﻜﻭﻥ ﻁﺭﻕ ﺍﻝﺘﺼﻨﻴﻊ ﻝﻠﺘﺤﻀﻴﺭﺍﺕ ﺍﻝﺘﺠﺭﻴﺒﻴﺔ ﺘﻤﺎﺜل ﻁﺭﻕ ﺍﻝﺘﺼﻨﻴﻊ ﺍﻝﺘﻲ‬
‫ﺴﺘﺘﺒﻊ ﻓﻲ ﺍﻝﺘﺤﻀﻴﺭﺍﺕ ﺍﻝﺼﻨﺎﻋﻴﺔ ﻭﺃﻥ ﻴﻘﺩﻡ ﻤﺴﺘﺤﻀﺭ ﺒﻨﻔﺱ ﺍﻝﻤﻭﺍﺼﻔﺎﺕ ﻭﺍﻝﺠﻭﺩﺓ‬
‫ﻝﻠﻤﺴﺘﺤﻀﺭ ﺍﻝﺫﻱ ﺴﻴﻁﺭﺡ ﻓﻲ ﺍﻷﺴﻭﺍﻕ ‪ .‬ﻴﻔﻀل ﺇﺫﺍ ﻜﺎﻥ ﻤﻤﻜﻨﺎ ﺍﺴﺘﺨﺩﺍﻡ ﺃﺭﻗﺎﻡ‬
‫ﺘﺤﻀﻴﺭﺍﺕ ﻤﺨﺘﻠﻔﺔ ﻤﻥ ﺍﻝﻤﻭﺍﺩ ﺍﻷﻭﻝﻴﺔ ﺍﻝﻔﻌﺎﻝﺔ ﻓﻲ ﺘﺼﻨﻴﻊ ﺍﻝﺘﺤﻀﻴﺭﺍﺕ ﺍﻝﺘﺠﺭﻴﺒﻴﺔ‬
‫ﻝﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ‪.‬‬
‫ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻴﺠﺏ ﺃﻥ ﺘﺠﺭﻯ ﻝﻜل ﺸﻜل ﺼﻴﺩﻻﻨﻲ ﻭﻝﻜل ﻋﻴﺎﺭ ﻤﺴﺘﻘل ﻭﻝﻜل ﺤﺠﻡ‬
‫ﺘﻌﺒﺌﺔ ﺇﻻ ﻓﻲ ﺤﺎﻝﺔ ﺇﺠﺭﺍﺀ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺒﻁﺭﻴﻘﺔ ﺍﻝﺘﻌﻘﻴﻑ)‪ ( Bracketing‬ﺃﻭ‬
‫ﺒﻁﺭﻴﻘﺔ ﺍﻝﺘﺼﻔﻴﻑ ) ‪.( Matrixing‬‬

‫ﻴﻤﻜﻥ ﺘﻘﺩﻴﻡ ﺒﻴﺎﻨﺎﺕ ﺇﻀﺎﻓﻴﺔ ﺘﺩﻋﻡ ﺍﻝﺩﺭﺍﺴﺎﺕ‪.‬‬

‫‪١٢‬‬
‫‪ ٤,٢,٢‬ﻨﻅﺎﻡ ﺍﻝﻌﺒﻭﺓ ﻭ ﺍﻹﻏﻼﻕ ‪Container Closure System‬‬

‫ﻴﺠﺏ ﺃﻥ ﺘﺠﺭﻯ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﻠﻤﺴﺘﺤﻀﺭ ﻓﻲ ﻨﻔﺱ ﻨﻅﺎﻡ ﺍﻝﻌﺒﻭﺓ ﻭﺍﻹﻏﻼﻕ‬


‫ﺍﻝﻤﺴﺘﺨﺩﻡ ﻓﻲ ﺍﻝﺘﺨﺯﻴﻥ ﻭﺍﻝﺘﻭﺯﻴﻊ ﺃﻭ ﺍﻝﺫﻱ ﻴﻤﺎﺜﻠﻪ)ﺒﻤﺎ ﻓﻲ ﺫﻝﻙ ﺍﻝﺘﻌﺒﺌﺔ ﻭﺍﻝﻌﻨﻭﻨﺔ‬
‫ﺍﻝﺜﺎﻨﻭﻴﺔ ‪ ،‬ﺤﻴﺜﻤﺎ ﺍﻨﻁﺒﻕ ﺫﻝﻙ(‪.‬‬
‫ﻴﻤﻜﻥ ﻷﻱ ﺩﺭﺍﺴﺔ ﺜﺒﺎﺕ ﻤﺴﺭﻋﺔ ﺘﺘﻡ ﻤﺒﺎﺸﺭﺓ ﻋﻠﻰ ﺍﻝﻤﺴﺘﺤﻀﺭ ﺨﺎﺭﺝ ﺍﻝﻌﺒﻭﺓ‬
‫ﺃﻭ ﺃﻱ ﻤﻭﺍﺩ ﺘﻌﺒﺌﺔ ﺃﺨﺭﻯ ‪ ،‬ﺃﻥ ﺘﻘﺩﻡ ﻤﻌﻠﻭﻤﺎﺕ ﻤﻔﻴﺩﺓ ﺩﺍﻋﻤﺔ ﻝﻠﺩﺭﺍﺴﺔ‪.‬‬

‫‪ ٥,٢,٢‬ﺍﻝﻤﻭﺍﺼﻔﺔ ‪Specification‬‬

‫ﻴﺠﺏ ﺃﻥ ﺘﺘﻀﻤﻥ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﻠﻤﺴﺘﺤﻀﺭ ﺍﻝﺠﺎﻫﺯ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺘﻲ‬


‫ﺘﻜﺸﻑ ﺍﻝﺘﺒﺩﻻﺕ ﺨﻼل ﻓﺘﺭﺓ ﺍﻝﺘﺨﺯﻴﻥ ﻭﺍﻝﺘﻲ ﺘﺅﺜﺭ ﻓﻲ ﺍﻝﺠﻭﺩﺓ ﻭﺍﻝﻔﻌﺎﻝﻴﺔ‬
‫ﻭﺍﻝﺴﻼﻤﺔ ‪.‬ﺍﻻﺨﺘﺒﺎﺭﺍﺕ ﻴﺠﺏ ﺃﻥ ﺘﺸﻤل ﺍﻝﻔﺤﻭﺹ ﺍﻝﻔﻴﺯﻴﺎﺌﻴﺔ ﻭﺍﻝﻜﻴﻤﻴﺎﺌﻴﺔ‬
‫ﻭﺍﻝﺤﻴﻭﻴﺔ ﻭﺍﻝﺠﺭﺜﻭﻤﻴﺔ ‪ ،‬ﻜﻤﻴﺔ ﺍﻝﻤﺎﺩﺓ ﺍﻝﺤﺎﻓﻅﺔ ) ﻤﺜﺎل ‪ ،‬ﻤﻀﺎﺩﺍﺕ ﺍﻝﺘﺄﻜﺴﺩ ‪،‬‬
‫ﺍﻝﻤﻭﺍﺩ ﺍﻝﺤﺎﻓﻅﺔ ﺍﻝﻤﻀﺎﺩﺓ ﻝﻠﺠﺭﺍﺜﻴﻡ( ‪ ،‬ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﻭﻅﺎﺌﻑ) ﻤﺜﺎل ‪ ،‬ﻁﺭﻕ ﻨﻅﺎﻡ‬
‫ﺍﻝﺠﺭﻋﺎﺕ ﺍﻝﺩﻭﺍﺌﻴﺔ(‪ .‬ﻜﻤﺎ ﺃﻨﻪ ﻴﺠﺏ ﺘﻁﺒﻴﻕ ﺨﻁﻁ ﺘﺤﻠﻴل ﻤﺅﺸﺭﺓ ﻝﻠﺜﺒﺎﺕ ﻗﺩ ﺘﻡ‬
‫ﺍﻝﺘﺤﻘﻕ ﻤﻥ ﺼﻼﺤﻴﺘﻬﺎ‪.‬‬
‫ﺇﻥ ﻤﻌﻴﺎﺭﻗﺒﻭل ﻋﻤﺭ ﺍﻝﺩﻭﺍﺀ ﻋﻠﻰ ﺍﻝﺭﻑ ﻴﺠﺏ ﺃﻥ ﻴﺘﻡ ﺍﻝﻭﺼﻭل ﺇﻝﻴﻪ ﺒﻌﺩ ﺍﻷﺨﺫ‬
‫ﺒﻌﻴﻥ ﺍﻹﻋﺘﺒﺎﺭ ﺠﻤﻴﻊ ﺍﻝﻤﻌﻠﻭﻤﺎﺕ ﺍﻝﻤﺘﻭﻓﺭﺓ ‪ .‬ﻗﺩ ﻴﻜﻭﻥ ﻤﻥ ﺍﻝﻤﻨﺎﺴﺏ ﻭﺠﻭﺩ‬
‫ﺇﺨﺘﻼﻑ ﻤﺒﺭﺭ ﺒﻴﻥ ﻋﻤﺭ ﺍﻝﺩﻭﺍﺀ ﻋﻠﻰ ﺍﻝﺭﻑ ﻭﺒﻴﻥ ﻤﻌﻴﺎﺭ ﻗﺒﻭل ﻭﺘﺤﺭﻴﺭ‬
‫ﺍﻝﺘﺤﻀﻴﺭﺓ ﺒﺎﻻﺴﺘﻨﺎﺩ ﻋﻠﻰ ﺘﻘﻴﻴﻡ ﺍﻝﺜﺒﺎﺕ ﻭﺍﻝﺘﺒﺩﻻﺕ ﺍﻝﺘﻲ ﻴﺘﻡ ﻤﻼﺤﻅﺘﻬﺎ ﺃﺜﻨﺎﺀ‬
‫ﻓﺘﺭﺓ ﺍﻝﺘﺨﺯﻴﻥ ‪ .‬ﺇﻥ ﺃﻱ ﺇﺨﺘﻼﻑ ﺒﻴﻥ ﻤﻌﺎﻴﻴﺭ ﻗﺒﻭل ﺍﻝﺘﺤﺭﻴﺭ ﻭﻋﻤﺭ ﺍﻝﺩﻭﺍﺀ‬
‫ﻋﻠﻰ ﺍﻝﺭﻑ ﻝﻤﺤﺘﻭﻯ ﻭﻓﻌﺎﻝﻴﺔ ﺍﻝﻌﻭﺍﻤل ﺍﻝﺤﺎﻓﻅﺔ ﻤﻥ ﺍﻝﺠﺭﺍﺜﻴﻡ ﻓﻲ ﺍﻝﺸﻜل‬
‫ﺍﻝﺼﻴﺩﻻﻨﻲ ﺍﻝﺠﺎﻫﺯ ﻴﺠﺏ ﺃﻥ ﺘﺴﻨﺩ ﺒﻤﻌﺎﻴﺭﺍﺕ ﻗﺩ ﺘﻡ ﺍﻝﺘﺤﻘﻕ ﻤﻥ ﺼﻼﺤﻴﺘﻬﺎ‬
‫ﺘﺒﻴﻥ ﺍﻝﻤﺤﺘﻭﻯ ﻤﻥ ﺍﻝﻤﻭﺍﺩ ﺍﻝﺤﺎﻓﻅﺔ ﺨﻼل ﻓﺘﺭﺓ ﺍﻝﺩﺭﺍﺴﺔ ‪.‬‬
‫ﻴﺠﺏ ﺇﺨﺘﺒﺎﺭ ﺘﺤﻀﻴﺭﺓ ﺘﺠﺭﻴﺒﻴﺔ ﻭﺍﺤﺩﺓ ﻝﻠﺸﻜل ﺍﻝﺼﻴﺩﻻﻨﻲ ﺍﻝﺠﺎﻫﺯ ﻴﺘﻡ ﺇﺠﺭﺍﺀ‬
‫ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺘﺤﻘﻕ ﻤﻥ ﻓﻌﺎﻝﻴﺔ ﻭﺘﺭﻜﻴﺯ ﺍﻝﻌﻭﺍﻤل ﺍﻝﺤﺎﻓﻅﺔ ﺨﻼل ﻓﺘﺭﺓ ﻋﻤﺭ‬
‫ﺍﻝﺩﻭﺍﺀ ﻋﻠﻰ ﺍﻝﺭﻑ ‪ ،‬ﻭﺫﻝﻙ ﺒﻐﺽ ﺍﻝﻨﻅﺭ ﻓﻴﻤﺎ ﺇﺫﺍ ﻜﺎﻥ ﻫﻨﺎﻙ ﺇﺨﺘﻼﻑ ﺒﻴﻥ‬
‫ﻤﻌﺎﻴﻴﺭ ﻗﺒﻭل ﻋﻤﺭ ﺍﻝﺩﻭﺍﺀ ﻋﻠﻰ ﺍﻝﺭﻑ ﻭﺍﻝﺘﺤﺭﻴﺭ ﻝﻜﻤﻴﺔ ﺍﻝﻌﻭﺍﻤل ﺍﻝﺤﺎﻓﻅﺔ‪.‬‬

‫ﺘﻜﺭﺍﺭﻴﺔ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ‪Testing Frequency‬‬ ‫‪٦,٢,٢‬‬

‫ﻓﻲ ﺤﺎﻝﺔ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻓﺈﻥ ﺘﻜﺭﺍﺭﻴﺔ ﺍﻝﻔﺤﻭﺹ ﻴﺠﺏ ﺃﻥ ﺘﻜﻭﻥ‬
‫ﻜﺎﻓﻴﺔ ﻝﺘﺤﻘﻴﻕ ﻤﻠﻑ ﺜﺒﺎﺕ ﺍﻝﻤﺴﺘﺤﻀﺭ ﺍﻝﺠﺎﻫﺯ ‪ .‬ﻓﻲ ﺤﺎﻝﺔ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ‬
‫ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻓﺈﻥ ﺘﻜﺭﺍﺭﻴﺔ ﺍﻝﻔﺤﻭﺹ ﻴﺠﺏ ﺃﻥ ﺘﺘﻡ ﻜل ﺜﻼﺜﺔ ﺃﺸﻬﺭ ﺨﻼل‬

‫‪١٣‬‬
‫ﺍﻝﺴﻨﺔ ﺍﻷﻭﻝﻰ ﻭﻜل ﺴﺘﺔ ﺃﺸﻬﺭ ﺨﻼل ﺍﻝﺴﻨﺔ ﺍﻝﺜﺎﻨﻴﺔ ﻭﺴﻨﻭﻴﺎ ﺒﻌﺩ ﺫﻝﻙ ﻭﻓﻘﺎ ﻝﻌﻤﺭ‬
‫ﺍﻝﺩﻭﺍﺀ ﻋﻠﻰ ﺍﻝﺭﻑ ﺍﻝﻤﻘﺘﺭﺡ‪.‬‬
‫ﻓﻲ ﺤﺎﻝﺔ ﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺴﺭﻋﺔ ﻓﺈﻥ ﺍﻝﺤﺩﻭﺩ ﺍﻝﺩﻨﻴﺎ ﻝﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﻤﺩﺓ ﺴﺘﺔ‬
‫ﺃﺸﻬﺭﻫﻲ ﺜﻼﺙ ﻨﻘﺎﻁ‪ ،‬ﺘﺸﻤل ﺍﻝﺒﺩﺍﻴﺔ ﻭﺍﻝﻨﻬﺎﻴﺔ )ﻤﺜل ‪ ٠،٣،٦‬ﺃﺸﻬﺭ (‪.‬‬
‫ﻋﻨﺩ ﺇﻴﻘﺎﻑ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﻓﻲ ﻤﻨﺘﺼﻑ ﻓﺘﺭﺓ ﺍﻝﺘﺨﺯﻴﻥ ﺒﺴﺒﺏ ﺘﺒﺩﻻﺕ ﺸﺩﻴﺩﺓ ﻓﻲ‬
‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺴﺭﻋﺔ ﻋﻨﺩﻫﺎ ﻴﻁﻠﺏ ﺇﺠﺭﺍﺀ ﺃﺭﺒﻊ ﻨﻘﺎﻁ ﺇﺨﺘﺒﺎﺭ ﻜﺤﺩ ﺃﺩﻨﻰ‬
‫ﺒﺤﻴﺙ ﺘﺸﻤل ﺯﻤﻥ ﺍﻝﺒﺩﺍﻴﺔ ﻭﺍﻝﻨﻬﺎﻴﺔ )ﻤﺜل ‪ ٠،٣،٦،١٢‬ﺸﻬﺭ( ﻝﺩﺭﺍﺴﺔ ‪ ١٢‬ﺸﻬﺭ‬
‫ﻤﻘﺘﺭﺤﺔ‪.‬‬
‫ﺍﻝﺘﺼﺎﻤﻴﻡ ﺍﻝﻤﺨﺘﺼﺭﺓ ﻤﺜل ﺍﻝﺘﺼﻔﻴﻑ ﻭﺍﻝﺘﻌﻘﻴﻑ ‪Bracketing & Matrixing‬‬
‫‪ ،‬ﻭﺍﻝﺘﻲ ﻴﺘﻡ ﻓﻴﻬﺎ ﺇﺨﺘﺼﺎﺭ ﺘﻜﺭﺍﺭﻴﺔ ﺍﻝﻔﺤﻭﺹ ﺃﻭ ﺃﻥ ﻤﺠﻤﻭﻉ ﺒﻌﺽ ﺍﻝﺒﻨﻭﺩ‬
‫ﻻﻴﺘﻡ ﺇﺨﺘﺒﺎﺭﻫﺎ ﺇﻁﻼﻗﺎ ‪ ،‬ﻓﺈﻨﻪ ﻴﻤﻜﻥ ﺘﻁﺒﻴﻘﻬﺎ ﺇﺫﺍ ﻜﺎﻥ ﺫﻝﻙ ﻤﺒﺭﺭﺍ‪.‬‬

‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ‪Storage Conditions‬‬ ‫‪٧,٢,٢‬‬

‫ﺒﺸﻜل ﻋﺎﻡ ‪ ،‬ﻴﺠﺏ ﺘﻘﻴﻴﻡ ﺍﻝﻤﺴﺘﺤﻀﺭ ﺍﻝﺠﺎﻫﺯ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ )ﺘﺤﻤل ﻤﻨﺎﺴﺏ(‬
‫ﺘﺨﺘﺒﺭ ﺜﺒﺎﺘﻬﺎ ﺍﻝﺤﺭﺍﺭﻱ ﻭﻜﺫﻝﻙ ﺇﺫﺍ ﺍﻨﻁﺒﻕ ﻋﻠﻴﻬﺎ ﺫﻝﻙ ﺤﺴﺎﺴﻴﺘﻬﺎ ﻝﻠﺭﻁﻭﺒﺔ ‪.‬‬
‫ﻴﺠﺏ ﺃﻥ ﺘﻜﻭﻥ ﻓﺘﺭﺓ ﺍﻝﺩﺭﺍﺴﺔ ﻭﺸﺭﻭﻁﻬﺎ ﻜﺎﻓﻴﺔ ﻝﺘﻐﻁﻲ ﺍﻝﺘﺨﺯﻴﻥ ﻭﺍﻝﺸﺤﻥ‬
‫ﻭﺍﻹﺴﺘﻌﻤﺎل ﺍﻝﻼﺤﻕ‪.‬‬
‫ﻴﺠﺏ ﺃﻥ ﺘﺠﺭﻯ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﻠﻤﺴﺘﺤﻀﺭ ﺍﻝﺠﺎﻫﺯ ﺒﻌﺩ ﺍﻝﻤﺯﺝ ﻭﺍﻝﺘﻤﺩﻴﺩ‪ ،‬ﺇﺫﺍ‬
‫ﺍﻨﻁﺒﻕ ﺫﻝﻙ‪ ،‬ﻝﺘﻌﻁﻲ ﻤﻌﻠﻭﻤﺎﺕ ﻝﻌﻨﻭﻨﺔ ﺍﻝﻤﺴﺘﺤﻀﺭ‪ ،‬ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ‪،‬‬
‫ﻭﺼﻼﺤﻴﺔ ﺍﻝﻤﺴﺘﺤﻀﺭ ﺨﻼل ﻓﺘﺭﺓ ﺍﻻﺴﺘﻌﻤﺎل ﺒﻌﺩ ﺍﻝﻤﺯﺝ ﻭﺍﻝﺘﻤﺩﻴﺩ‪.‬‬
‫ﺍﻻﺨﺘﺒﺎﺭﺍﺕ ﻴﺠﺏ ﺃﻥ ﺘﺠﺭﻯ ﻋﻠﻰ ﺍﻝﻤﺴﺘﺤﻀﺭ ﺒﻌﺩ ﻤﺯﺠﻪ ﺃﻭ ﺘﻤﺩﻴﺩﻩ ﺨﻼل‬
‫ﻓﺘﺭﺓ ﺍﻻﺴﺘﻌﻤﺎل ﺍﻝﻤﻘﺘﺭﺤﺔ ﻭﺫﻝﻙ ﻋﻠﻰ ﻋﻴﻨﺎﺕ ﺘﺠﺭﻴﺒﻴﺔ ﻜﺠﺯﺀ ﻤﻥ ﺩﺭﺍﺴﺎﺕ‬
‫ﺍﻝﺜﺒﺎﺕ ﻭﺃﻥ ﺘﺠﺭﻯ ﻨﻘﺎﻁ ﺍﻝﻤﻌﺎﻴﺭﺓ ﻓﻲ ﺒﺩﺍﻴﺔ ﺍﻻﺴﺘﻌﻤﺎل ﻭﻨﻬﺎﻴﺘﻪ‪ ،‬ﺇﺫﺍ ﻝﻡ ﺘﺘﻭﻓﺭ‬
‫ﻨﺘﺎﺌﺞ ﻜﺎﻤﻠﺔ ﻋﻥ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻁﻴﻠﺔ ﻓﺘﺭﺓ ﻋﻤﺭ ﺍﻝﺩﻭﺍﺀ ﻋﻠﻰ ﺍﻝﺭﻑ ﻭﺫﻝﻙ‬
‫ﻗﺒل ﺘﻘﺩﻴﻡ ﻤﻠﻑ ﺘﺴﺠﻴل ﺍﻝﺩﻭﺍﺀ ‪ ،‬ﺃﻱ ﺒﻌﺩ ﺴﺘﺔ ﺃﺸﻬﺭ ﺃﻭ ﺁﺨﺭ ﻨﻘﻁﺔ ﻤﻌﺎﻴﺭﺓ‪.‬‬
‫ﺒﺸﻜل ﻋﺎﻡ ﻻﻴﻭﺠﺩ ﺤﺎﺠﺔ ﻝﺘﻜﺭﺍﺭ ﺘﻠﻙ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﻓﻲ ﺍﻝﺘﺤﻀﻴﺭﺍﺕ‬
‫ﺍﻝﻤﻨﺼﻭﺹ ﻋﻠﻴﻬﺎ ﻓﻲ ﺍﻝﺩﺭﺍﺴﺔ‪.‬‬
‫ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻝﻠﺨﻴﺎﺭ )ﺃ( ﻴﺠﺏ ﺃﻥ ﺘﻐﻁﻲ ﻤﺎ ﻻ ﻴﻘل ﻋﻥ ﺴﺘﺔ‬
‫ﺃﺸﻬﺭ ﻭﻓﺘﺭﺓ ‪ ١٢‬ﺸﻬﺭ ﻝﻠﺨﻴﺎﺭ )ﺏ( ﻓﻲ ﻓﺘﺭﺓ ﺘﻘﺩﻴﻡ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﻜﻤﺎ ﻴﺠﺏ‬
‫ﺃﻥ ﺘﺴﺘﻤﺭ ﻝﻤﺩﺓ ﻤﻥ ﺍﻝﺯﻤﻥ ﺘﻜﻔﻲ ﻝﺘﻐﻁﻴﺔ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ‪ .‬ﻴﺠﺏ ﺘﻘﺩﻴﻡ‬
‫ﺒﻴﺎﻨﺎﺕ ﺇﻀﺎﻓﻴﺔ ﺘﻡ ﺘﺠﻤﻴﻌﻬﺎ ﺨﻼل ﻓﺘﺭﺓ ﺍﻝﺘﻘﻴﻴﻡ ﻝﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﻓﻲ ﺤﺎل ﺘﻡ‬
‫ﻁﻠﺒﻬﺎ ﻤﻥ ﺍﻝﺴﻠﻁﺎﺕ ﺍﻝﺼﺤﻴﺔ ‪ .‬ﺒﻴﺎﻨﺎﺕ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺴﺭﻋﺔ ﻭﻤﻥ ﺸﺭﻭﻁ‬
‫ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺘﻭﺴﻁﺔ ﻴﻤﻜﻥ ﺃﻥ ﺘﺴﺘﻌﻤل ﻝﺘﻘﻴﻴﻡ ﺘﺄﺜﻴﺭ ﺘﻌﺭﺽ ﺍﻝﻤﺴﺘﺤﻀﺭ‬
‫ﻝﺸﺭﻭﻁ ﺘﺨﺘﻠﻑ ﻋﻥ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺼﺭﺡ ﺒﻬﺎ ﻓﻲ ﺍﻝﻌﻨﻭﻨﺔ ) ﻤﺜل ﺍﻝﺘﻲ‬
‫ﺘﺤﺼل ﺨﻼل ﻓﺘﺭﺓ ﺍﻝﺸﺤﻥ(‪.‬‬

‫‪١٤‬‬
‫ﺇﻥ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺴﺭﻋﺔ ﻭﺍﻝﻤﺘﻭﺴﻁﺔ ﻭﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻝﻠﻤﺴﺘﺤﻀﺭ ﺍﻝﺠﺎﻫﺯ‬
‫ﻴﺘﻡ ﺫﻜﺭﻫﺎ ﺒﺎﻝﺘﻔﺼﻴل ﻓﻲ ﺍﻝﺒﻨﻭﺩ ﺍﻝﻤﺫﻜﻭﺭﺓ ﺃﺩﻨﺎﻩ‪ .‬ﺘﻁﺒﻕ ﺍﻝﺤﺎﻝﺔ ﺍﻝﻌﺎﻤﺔ ﺇﺫﺍ ﻝﻡ‬
‫ﺘﻜﻥ ﺍﻝﻔﺼﻭل ﺍﻝﻼﺤﻘﺔ ﺘﻐﻁﻲ ﺍﻝﻤﺴﺘﺤﻀﺭ ﺍﻝﺠﺎﻫﺯ‪ .‬ﻴﻤﻜﻥ ﺍﺴﺘﺨﺩﺍﻡ ﺸﺭﻭﻁ‬
‫ﺘﺨﺯﻴﻥ ﻤﺨﺘﻠﻔﺔ ﺇﺫﺍ ﺘﻡ ﺘﺒﺭﻴﺭ ﺫﻝﻙ‪.‬‬

‫‪ ١,٧,٢,٢‬ﺤﺎﻝﺔ ﻋﺎﻤﺔ ‪General case‬‬

‫ﺍﻝﻔﺘﺭﺓ ﺍﻝﺯﻤﻨﻴﺔ ﺍﻝﺩﻨﻴﺎ ﺍﻝﺘﻲ‬ ‫ﻨﻭﻉ ﺍﻝﺩﺭﺍﺴﺔ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ‬


‫ﺘﻐﻁﻴﻬﺎ ﺍﻝﺒﻴﺎﻨﺎﺕ ﻓﻲ‬
‫ﺯﻤﻥ ﺘﻘﺩﻴﻡ ﻤﻠﻑ‬
‫ﺍﻝﺘﺴﺠﻴل‬
‫‪ ٦ 25°C ± 2°C/60% RH ± 5% RH‬ﺸﻬﻭﺭ )ﺍﻝﺨﻴﺎﺭ ﺃ (‬ ‫ﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‬
‫‪ ١٢ or‬ﺸﻬﺭ ) ﺍﻝﺨﻴﺎﺭ ﺏ(‬ ‫*‬
‫‪30°C ± 2°C/65% RH ± 5% RH‬‬
‫‪ ٦ 30°C ± 2°C/65% RH ± 5% RH‬ﺸﻬﻭﺭ‬ ‫ﻤﺘﻭﺴﻁﺔ‬
‫‪ ٦ 40°C ± 2°C/75% RH ± 5% RH‬ﺸﻬﻭﺭ‬ ‫ﻤﺴﺭﻋﺔ‬

‫*ﻋﻠﻰ ﻤﻘﺩﻡ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﺃﻥ ﻴﻘﺭﺭ ﻓﻲ ﺇﺠﺭﺍﺀ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﺒﺸﺭﻭﻁ‬
‫‪ 25°C ± 2°C/60% RH ± 5% RH‬ﺃﻭ ‪ 30°C ± 2°C/65% RH ± 5% RH‬ﻓﻲ ﺤﺎل‬
‫ﺇﺠﺭﺍﺀ ﺍﻝﺨﻴﺎﺭ ﺍﻝﺜﺎﻨﻲ ‪ ،‬ﻋﻨﺩﻫﺎﻻﻴﻭﺠﺩ ﺤﺎﺠﺔ ﻹﺠﺭﺍﺀ ﺍﻝﺩﺭﺍﺴﺎﺕ ﺒﺸﺭﻭﻁ ﻤﺘﻭﺴﻁﺔ‪.‬‬

‫ﻋﻨﺩ ﺤﺩﻭﺙ ﺘﺒﺩﻻﺕ ﻤﻠﺤﻭﻅﺔ ﻓﻲ ﺃﻱ ﻭﻗﺕ ﺨﻼل ﻓﺘﺭﺓ ﺍﻝﺴﺘﺔ ﺃﺸﻬﺭ ﻓﻲ ﻨﺘﺎﺌﺞ ﻤﺭﺤﻠﺔ ﺸﺭﻭﻁ‬
‫ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺴﺭﻋﺔ ‪ ،‬ﻋﻨﺩﻫﺎ ﻴﻁﻠﺏ ﺇﺠﺭﺍﺀ ﺇﺨﺘﺒﺎﺭﺍﺕ ﺇﻀﺎﻓﻴﺔ ﻓﻲ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺘﻭﺴﻁﺔ‬
‫ﻭﺃﻥ ﺘﻘﻴﻡ ﺒﺎﻝﻤﻘﺎﺭﻨﺔ ﻤﻊ ﺍﻝﺘﺒﺩﻻﺕ ﺍﻝﻤﻠﺤﻭﻅﺔ ﺍﻝﻤﻘﺎﺴﺔ ﺴﺎﺒﻘﺎ‪ .‬ﻴﺠﺏ ﺃﻥ ﻴﺘﻀﻤﻥ ﺍﻝﻁﻠﺏ ﺍﻷﻭﻝﻲ‬
‫ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﺴﺘﺔ ﺃﺸﻬﺭ ﻋﻠﻰ ﺍﻷﻗل ﻤﻥ ﺃﺼل ﺍل ‪ ١٢‬ﺸﻬﺭ ﻓﻲ ﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ‬
‫ﺍﻝﻤﺭﺤﻠﺔ ﺍﻝﻤﺘﻭﺴﻁﺔ‪.‬‬

‫ﺒﺸﻜل ﻋﺎﻡ ‪ ،‬ﻴﻌﺭﻑ ﺍﻝﺘﺒﺩل ﺍﻝﻤﻬﻡ ﻝﻠﻤﺴﺘﺤﻀﺭ ﺍﻝﺠﺎﻫﺯ ﺒﺄﻨﻪ‪:‬‬


‫‪ -١‬ﺘﺒﺩل ﻓﻲ ﺍﻝﻔﻌﺎﻝﻴﺔ ﺒﻨﺴﺒﺔ ‪ %٥‬ﻋﻥ ﺍﻝﻘﻴﻤﺔ ﺍﻷﻭﻝﻴﺔ )ﺒﺩﺍﻴﺔ ﺍﻝﺩﺭﺍﺴﺔ( ‪ :‬ﺃﻭ ﺍﻝﻔﺸل ﻓﻲ ﺘﺤﻘﻴﻕ‬
‫ﻤﻌﺎﻴﻴﺭ ﺍﻝﻔﻌﺎﻝﻴﺔ ﺍﻝﻤﻘﺒﻭﻝﺔ ﻋﻨﺩ ﺍﺴﺘﻌﻤﺎل ﺨﻁﻁ ﺤﻴﻭﻴﺔ ﺃﻭ ﻤﻨﺎﻋﻴﺔ؛‬
‫‪ -٢‬ﺃﻱ ﻤﻭﺍﺩ ﺘﺨﺭﺏ ﺘﺯﻴﺩ ﻋﻥ ﺍﻝﺤﺩﻭﺩ ﺍﻝﻤﺴﻤﻭﺡ ﺒﻬﺎ‪.‬‬
‫‪ -٣‬ﺍﻝﻔﺸل ﻓﻲ ﺘﺤﻘﻴﻕ ﺍﻝﻤﻌﺎﻴﻴﺭ ﺍﻝﻤﻘﺒﻭﻝﺔ ﺍﻝﻤﺘﻌﻠﻘﺔ ﺒﺎﻝﻤﻅﻬﺭ ‪ ،‬ﺍﻝﺨﻭﺍﺹ ﺍﻝﻔﻴﺯﻴﺎﺌﻴﺔ ‪ ،‬ﺇﺨﺘﺒﺎﺭﺍﺕ‬
‫ﺍﻝﻭﻅﺎﺌﻑ ) ﻤﺜل‪ ،‬ﺍﻝﻠﻭﻥ ‪ ،‬ﻓﺼل ﺍﻝﻁﻭﺭ‪ ،‬ﺇﻋﺎﺩﺓ ﺍﻝﺘﻌﻠﻴﻕ‪ ،‬ﺍﻝﺘﺭﺴﺏ ﺒﺸﻜل ﺍﻝﻜﻌﻜﺔ‪ ،‬ﺍﻝﻘﺴﺎﻭﺓ‪،‬‬
‫ﻜﻤﻴﺔ ﺍﻝﻤﺎﺩﺓ ﻓﻲ ﻜل ﺠﺭﻋﺔ (؛ ﻋﻠﻰ ﺃﻴﺔ ﺤﺎل ﻴﻤﻜﻥ ﺘﻭﻗﻊ ﺒﻌﺽ ﺍﻝﺘﺒﺩﻻﺕ ﺍﻝﺘﻲ ﺘﻌﺯﻯ ﺇﻝﻰ‬
‫ﺍﻝﺨﻭﺍﺹ ﺍﻝﻔﻴﺯﻴﺎﺌﻴﺔ ) ﻤﺜل ‪ ،‬ﻝﻴﻭﻨﺔ ﺍﻝﺘﺤﺎﻤﻴل‪ ،‬ﺇﻨﺼﻬﺎﺭ ﺍﻝﻜﺭﻴﻤﺎﺕ‪ ،‬ﻓﻘﺩﺍﻥ ﺠﺯﺀ ﻤﻥ ﺍﻝﻤﺎﺩﺓ‬
‫ﺍﻝﻼﺼﻘﺔ ﻝﻠﻤﺴﺤﻀﺭﺍﺕ ﺍﻝﻤﻁﺒﻘﺔ ﻋﻠﻰ ﺍﻝﺠﻠﺩ ﻜﻠﺼﺎﻗﺎﺕ(‪:‬‬

‫‪١٥‬‬
‫ﻭﻜﺫﻝﻙ‪ ،‬ﺒﺤﺴﺏ ﻁﺒﻴﻌﺔ ﺍﻝﺸﻜل ﺍﻝﺼﻴﺩﻻﻨﻲ ‪:‬‬
‫‪ -٤‬ﺍﻝﻔﺸل ﻓﻲ ﺘﺤﻘﻴﻕ ﻤﺠﺎل ﺍﻝﻘﺒﻭل ﻝﺩﺭﺠﺔ ﺍﻝﺤﻤﻭﻀﺔ‪.‬‬
‫‪ -٥‬ﺍﻝﻔﺸل ﻓﻲ ﺘﺤﻘﻴﻕ ﻤﻌﺎﻴﻴﺭ ﺍﻝﻘﺒﻭل ﺒﺎﻝﻨﺴﺒﺔ ﻹﻨﺤﻼﻝﻴﺔ ‪ ١٢‬ﻭﺤﺩﺓ ﺠﺭﻋﺔ‪.‬‬

‫‪ ٢,٧,٢,٢‬ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺠﺎﻫﺯﺓ ﺍﻝﻤﻌﻠﺒﺔ ﻓﻲ ﺃﻭﻋﻴﺔ ﻏﻴﺭ ﻨﻔﻭﺫﺓ‬


‫‪Finished products packaged in impermeable container‬‬

‫ﺍﻝﺤﺴﺎﺴﻴﺔ ﻝﻠﺭﻁﻭﺒﺔ ﺇﺤﺘﻤﺎل ﻓﻘﺩﺍﻥ ﺍﻝﻤﺫﻴﺒﺎﺕ ﻻﻴﺸﻜل ﺇﻫﺘﻤﺎﻡ ﻝﻠﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺠﺎﻫﺯﺓ ﺍﻝﻤﻌﺒﺌﺔ ﻓﻲ‬
‫ﺃﻭﻋﻴﺔ ﻏﻴﺭ ﻨﻔﻭﺫﺓ ﻭﺍﻝﺘﻲ ﺘﺸﻜل ﺤﺎﺠﺯﺍ ﻜﺘﻴﻤﺎ ﺩﺍﺌﻤﺎ ﺘﻤﻨﻊ ﻋﺒﻭﺭ ﺍﻝﻤﺫﻴﺏ ﺃﻭ ﺍﻝﺭﻁﻭﺒﺔ ‪ .‬ﻭﻫﻜﺫﺍ‪،‬‬
‫ﻓﺈﻨﻪ ﻴﻤﻜﻥ ﺇﺠﺭﺍﺀ ﺩﺭﺍﺴﺔ ﺍﻝﺜﺒﺎﺕ ﻝﻠﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﻤﻌﺒﺄﺓ ﻓﻲ ﺃﻭﻋﻴﺔ ﻏﻴﺭ ﻨﻔﻭﺫﺓ ﺘﺤﺕ ﺃﻴﺔ ﺸﺭﻭﻁ‬
‫ﻤﺭﺍﻗﺒﺔ ﺃﻭ ﻓﻲ ﺸﺭﻭﻁ ﺍﻝﺭﻁﻭﺒﺔ ﺍﻝﻁﺒﻴﻌﻴﺔ‪.‬‬

‫‪ ٣,٧,٢,٢‬ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺠﺎﻫﺯﺓ ﺍﻝﻤﻌﺒﺄﺓ ﻓﻲ ﺃﻭﻋﻴﺔ ﻨﺼﻑ ﻨﻔﻭﺫﺓ‬


‫‪Finished products packaged in semi-permeable containers‬‬

‫ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺘﻲ ﺃﺴﺎﺴﻬﺎ ﻤﺎﺌﻲ ﺍﻝﻤﻌﻠﺒﺔ ﻓﻲ ﺃﻭﻋﻴﺔ ﻨﺼﻑ ﻨﻔﻭﺫﺓ ﻓﺈﻨﻪ ﻴﺠﺏ ﺃﻥ ﺘﻘﻴﻡ ﻤﻥ ﺤﻴﺙ‬
‫ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ ﺇﻀﺎﻓﺔ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻔﻴﺯﻴﺎﺌﻲ ﻭﺍﻝﻜﻴﻤﻴﺎﺌﻲ ﻭﺍﻝﺠﺭﺜﻭﻤﻲ ‪ .‬ﻴﻤﻜﻥ ﺃﻥ ﻴﺘﻡ ﻫﺫﺍ ﺍﻝﺘﻘﻴﻴﻡ ﺘﺤﺕ‬
‫ﺸﺭﻭﻁ ﻤﻨﺨﻔﻀﺔ ﺍﻝﺭﻁﻭﺒﺔ ﻜﻤﺎ ﺴﻴﺘﻡ ﻤﻨﺎﻗﺸﺘﻪ ﻻﺤﻘﺎ‪ .‬ﻭﺒﺸﻜل ﻨﻬﺎﺌﻲ ‪ ،‬ﻴﺠﺏ ﺃﻥ ﻴﻌﺭﺽ‬
‫ﻭﻴﻭﻀﺢ ﺒﺄﻥ ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺠﺎﻫﺯﺓ ﺍﻝﺘﻲ ﺃﺴﺎﺴﻬﺎ ﻤﺎﺌﻲ ﻭﺍﻝﻤﺨﺯﻨﺔ ﻓﻲ ﺃﻭﻋﻴﺔ ﻨﺼﻑ ﻨﻔﻭﺫﺓ‬
‫ﺒﺄﻨﻬﺎ ﻴﻤﻜﻥ ﺃﻥ ﺘﺘﺤﻤل ﻅﺭﻭﻑ ﺭﻁﻭﺒﺔ ﻤﻨﺨﻔﻀﺔ ﻨﺴﺒﻴﺎ‪.‬‬
‫ﻴﻤﻜﻥ ﺘﻁﻭﻴﺭ ﻭﺍﻹﺒﻼﻍ ﻋﻥ ﺒﻌﺽ ﺍﻝﻁﺭﻕ ﺍﻝﻤﻤﺎﺜﻠﺔ ﺍﻷﺨﺭﻯ ﻝﻠﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺘﻲ ﺃﺴﺎﺴﻬﺎ ﻏﻴﺭ‬
‫ﻤﺎﺌﻲ‪.‬‬

‫ﺍﻝﻔﺘﺭﺓ ﺍﻝﺯﻤﻨﻴﺔ ﺍﻝﺩﻨﻴﺎ‬ ‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ‬ ‫ﻨﻭﻉ‬


‫ﺍﻝﺘﻲ ﺘﻐﻁﻴﻬﺎ ﺍﻝﺒﻴﺎﻨﺎﺕ‬ ‫ﺍﻝﺩﺭﺍﺴﺔ‬
‫ﻓﻲ ﺯﻤﻥ ﺘﻘﺩﻴﻡ ﻤﻠﻑ‬
‫ﺍﻝﺘﺴﺠﻴل‬
‫‪ ٦‬ﺸﻬﻭﺭ )ﺍﻝﺨﻴﺎﺭ ﺃ (‬ ‫‪25°C ± 2°C/40% RH ± 5% RH or‬‬ ‫ﻁﻭﻴﻠﺔ‬
‫‪ ١٢‬ﺸﻬﺭ ) ﺍﻝﺨﻴﺎﺭ ﺏ(‬ ‫‪30°C ± 2°C/35% RH ± 5% RH‬‬ ‫ﺍﻷﻤﺩ‬
‫‪ ٦‬ﺸﻬﻭﺭ‬ ‫‪30°C ± 2°C/65% RH ± 5% RH‬‬ ‫ﻤﺘﻭﺴﻁﺔ‬
‫‪ ٦‬ﺸﻬﻭﺭ‬ ‫)‪40°C ± 2°C/not more than(NMT‬‬ ‫ﻤﺴﺭﻋﺔ‬
‫‪25% RH‬‬

‫‪١٦‬‬
‫ﻋﻨﺩ ﺤﺩﻭﺙ ﺃﻱ ﺘﺒﺩل ﺠﻭﻫﺭﻱ ﺨﻼل ﺍﻝﺴﺘﺔ ﺃﺸﻬﺭ ﻓﻲ ﺩﺭﺍﺴﺔ ﺍﻝﺜﺒﺎﺕ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺴﺭﻋﺔ‬
‫ﺒﺎﺴﺘﺜﻨﺎﺀ ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ ‪ ،‬ﻋﻨﺩﻫﺎ ﻴﺠﺏ ﺇﺠﺭﺍﺀ ﺩﺭﺍﺴﺎﺕ ﺜﺒﺎﺕ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺘﻭﺴﻁﺔ ﻜﻤﺎ ﻫﻭ‬
‫ﻤﻭﻀﺢ ﻓﻲ ﺍﻝﺤﺎﻝﺔ ﺍﻝﻌﺎﻤﺔ ﺒﺘﻘﻴﻴﻡ ﺘﺄﺜﻴﺭ ﺍﻝﺤﺭﺍﺭﺓ ﺒﺎﻝﺩﺭﺠﺔ ‪. 30°C‬‬
‫ﺇﻥ ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ ﺒﻜﻤﻴﺔ ﻤﻠﺤﻭﻅﺔ ﻓﻘﻁ ﺃﺜﻨﺎﺀ ﺩﺭﺍﺴﺔ ﺍﻝﺜﺒﺎﺕ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺴﺭﻋﺔ ﻻﻴﺤﺘﻡ ﺇﺠﺭﺍﺀ‬
‫ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺘﻭﺴﻁﺔ‪ .‬ﻋﻠﻰ ﺃﻴﺔ ﺤﺎل‪ ،‬ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ‬
‫ﻹﺜﺒﺎﺕ ﺃﻥ ﺍﻝﻤﺴﺘﺤﻀﺭ ﺍﻝﺠﺎﻫﺯ ﻝﻥ ﻴﺘﻌﺭﺽ ﻝﻔﻘﺩﺍﻥ ﻜﻤﻴﺔ ﻜﺒﻴﺭﺓ ﻤﻥ ﺍﻝﻤﺎﺀ ﺨﻼل ﻓﺘﺭﺓ ﻋﻤﺭ‬
‫ﺍﻝﺩﻭﺍﺀ ﻋﻠﻰ ﺍﻝﺭﻑ ﺇﺫﺍ ﺘﻡ ﺘﺨﺯﻴﻨﻪ ﺒﺩﺭﺠﺔ ﺤﺭﺍﺭﺓ ‪ 25°C‬ﻭﺒﺩﺭﺠﺔ ﺭﻁﻭﺒﺔ ﻨﺴﺒﻴﺔ ‪. 40% RH‬‬
‫ﺇﻥ ﻓﻘﺩﺍﻥ ‪ %٥‬ﻤﻥ ﺍﻝﻤﺎﺀ ﻋﻥ ﺍﻝﻜﻤﻴﺔ ﺍﻷﻭﻝﻴﺔ ﻓﻲ ﺒﺩﺍﻴﺔ ﺍﻝﺘﺼﻨﻴﻊ ﻴﻌﺘﺒﺭ ﺘﺒﺩل ﺠﻭﻫﺭﻱ‬
‫ﻝﻤﺴﺘﺤﻀﺭ ﻤﻌﺒﺄ ﻓﻲ ﺃﻭﻋﻴﺔ ﻨﺼﻑ ﻨﻔﻭﺫﺓ ﺒﻌﺩ ﺘﺨﺯﻴﻨﻪ ﻝﻤﺩﺓ ‪ ٣‬ﺃﺸﻬﺭ ﺒﺸﺭﻭﻁ‬
‫‪ . 40°C ± 2°C/not more than(NMT) 25% RH‬ﻋﻠﻰ ﺃﻴﺔ ﺤﺎل ‪ ،‬ﺒﺎﻝﻨﺴﺒﺔ ﻝﻠﻌﺒﻭﺍﺕ‬
‫ﺍﻝﺼﻐﻴﺭﺓ ) ‪١‬ﻤل ﺃﻭ ﺃﻗل( ﺃﻭ ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﻭﺤﻴﺩﺓ ﺍﻝﺠﺭﻋﺎﺕ ‪ ،‬ﻓﺈﻥ ﻓﻘﺩﺍﻥ ﻜﻤﻴﺔ ‪ %٥‬ﺃﻭ‬
‫ﺃﻜﺜﺭ ﻤﻥ ﺍﻝﻤﺎﺀ ﺒﻌﺩ ﺍﻝﺘﺨﺯﻴﻥ ﻝﻤﺩﺓ ‪ ٣‬ﺃﺸﻬﺭ ﺒﺸﺭﻭﻁ‬
‫‪ 40°C ± 2°C/not more than(NMT) 25% RH‬ﻓﺈﻨﻪ ﻴﻌﺘﺒﺭ ﻤﻘﺒﻭﻻ ‪ ،‬ﺇﺫﺍ ﺘﻡ ﺘﺒﺭﻴﺭ ﺫﻝﻙ‪.‬‬

‫ﺍﻝﻁﺭﻴﻘﺔ ﺍﻝﺒﺩﻴﻠﺔ ﻝﻠﺩﺭﺍﺴﺔ ﺒﺸﺭﻭﻁ ﻤﺭﺠﻌﻴﺔ ﻝﻠﺭﻁﻭﺒﺔ ﺍﻝﻨﺴﺒﻴﺔ ﻜﻤﺎ ﺃﻗﺘﺭﺡ ﻓﻲ ﺍﻝﺠﺩﻭل ﺃﻋﻼﻩ‬
‫) ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﺃﻭ ﺍﻝﻤﺴﺭﻋﺔ( ﻫﻭ ﺇﺠﺭﺍﺀ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻓﻲ ﺭﻁﻭﺒﺔ ﻨﺴﺒﻴﺔ‬
‫ﺃﻋﻠﻰ ﻭﻤﻥ ﺜﻡ ﺇﺸﺘﻘﺎﻕ ﻜﻤﻴﺔ ﺍﻝﻤﺎﺀ ﺍﻝﻤﻔﻘﻭﺩﺓ ﺒﻁﺭﻴﻘﺔ ﺤﺴﺎﺒﻴﺔ‪ .‬ﻴﻤﻜﻥ ﺇﻨﺠﺎﺯ ﺫﻝﻙ ﺘﺠﺭﻴﺒﻴﺎ ﻤﻥ‬
‫ﺨﻼل ﺘﺤﺩﻴﺩ ﻤﻌﺎﻤل ﺍﻝﻨﻔﻭﺫﻴﺔ ‪ permeation coefficient‬ﻝﻨﻅﺎﻡ ﺍﻝﺘﻌﺒﺌﺔ ﻭﺍﻹﻏﻼﻕ ﺃﻭ‪ ،‬ﻜﻤﺎ‬
‫ﻫﻭ ﻤﻭﻀﺢ ﻓﻲ ﺍﻝﻤﺜﺎل ﺍﻝﻤﺫﻜﻭﺭ ﺃﺩﻨﺎﻩ‪ ،‬ﺒﺎﺴﺘﺨﺩﺍﻡ ﻨﺴﺒﺔ ﺤﺴﺎﺒﻴﺔ ﻝﻔﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ ﺒﻴﻥ ﺸﺭﻁﻲ‬
‫ﺭﻁﻭﺒﺔ ﻓﻲ ﻨﻔﺱ ﺩﺭﺠﺔ ﺍﻝﺤﺭﺍﺭﺓ ‪ .‬ﻴﻤﻜﻥ ﺘﺤﺩﻴﺩ ﻋﺎﻤل ﺍﻝﻨﻔﻭﺫﻴﺔ ﺘﺠﺭﻴﺒﻴﺎ ﻝﻨﻅﺎﻡ ﺍﻝﺘﻌﺒﺌﺔ‬
‫ﻭﺍﻹﻏﻼﻕ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺃﺴﻭﺃ ﺴﻴﻨﺎﺭﻴﻭ ) ﻤﺜﺎل‪ ،.‬ﺃﻜﺒﺭ ﺘﻤﺩﻴﺩ ﻝﺴﻠﺴﻠﺔ ﺘﺭﺍﻜﻴﺯ( ﻝﻠﻤﺴﺘﺤﻀﺭ ﺍﻝﺠﺎﻫﺯ‬
‫ﺍﻝﻤﻘﺘﺭﺡ‪.‬‬

‫ﻤﺜﺎل ﻴﻭﻀﺢ ﻁﺭﻴﻘﺔ ﺘﺤﺩﻴﺩ ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ‪:‬‬


‫ﺇﻥ ﺍﻝﻁﺭﻴﻘﺔ ﺍﻝﻤﻨﺎﺴﺒﺔ ﻻﺸﺘﻘﺎﻕ ﻨﺴﺒﺔ ﻜﻤﻴﺔ ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ ﻝﻤﺴﺘﺤﻀﺭ ﻤﻌﺩ ﺒﻨﻅﺎﻡ ﺘﻌﺒﺌﺔ ﻭﺇﻏﻼﻕ ‪،‬‬
‫ﻭﺒﺤﺠﻡ ﻋﺒﻭﺓ ﻭﺘﻌﺒﺌﺔ ﻤﺤﺩﺩ ﻓﻲ ﺭﻅﻭﺒﺔ ﻨﺴﺒﻴﺔ ﻤﺭﺠﻌﻴﺔ ﻫﻭ ﻓﻲ ﻤﻀﺎﻋﻔﺔ ﻨﺴﺒﺔ ﻜﻤﻴﺔ ﻓﻘﺩﺍﻥ‬
‫ﺍﻝﻤﺎﺀ ﺍﻝﻤﻘﺎﺴﺔ ﺒﺭﻁﻭﺒﺔ ﻨﺴﺒﻴﺔ ﺒﻨﻔﺱ ﺩﺭﺠﺔ ﺍﻝﺤﺭﺍﺭﺓ ﻓﻲ ﻨﺴﺒﺔ ﺴﺭﻋﺔ ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ ﺍﻝﻤﺤﺩﺩﺓ ﻓﻲ‬
‫ﺍﻝﺠﺩﻭل ﺍﻝﻤﺫﻜﻭﺭ ﺃﺩﻨﺎﻩ ‪ .‬ﺇﻥ ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ ﺒﻨﺴﺏ ﺨﻁﻴﺔ ﻓﻲ ﺍﻝﺭﻁﻭﺒﺔ ﺍﻝﻨﺴﺒﻴﺔ ﺍﻝﺒﺩﻴﻠﺔ ﺨﻼل ﻓﺘﺭﺓ‬
‫ﺍﻝﺘﺨﺯﻴﻥ ﻴﺠﺏ ﺃﻥ ﻴﻭﻀﺢ ‪.‬‬
‫ﻋﻠﻰ ﺴﺒﻴل ﺍﻝﻤﺜﺎل ‪ ،‬ﺇﻥ ﻜﻤﻴﺔ ﻨﺴﺒﺔ ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ ﺍﻝﻤﻘﺎﺴﺔ ﺒﺎﻝﺩﺭﺠﺔ ‪ ، 40°C‬ﻭﺒﺭﻁﻭﺒﺔ ﻨﺴﺒﻴﺔ‬
‫‪ not more than(NMT) 25% RH‬ﻫﻲ ﻜﻤﻴﺔ ﻨﺴﺒﺔ ﺍﻝﻤﺎﺀ ﺍﻝﻤﻔﻘﻭﺩﺓ ﺍﻝﻤﻘﺎﺴﺔ ﺒﺭﻁﻭﺒﺔ ﻨﺴﺒﻴﺔ‬
‫‪ 75% RH‬ﻤﻀﺎﻋﻔﺔ ﺏ ‪ ، ٣,٠‬ﻤﻥ ﻨﺴﺒﺔ ﺴﺭﻋﺔ ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ ﺒﺎﻝﺸﺭﻭﻁ ﺫﺍﺕ ﺍﻝﻌﻼﻗﺔ‪.‬‬

‫‪١٧‬‬
‫ﺍﻝﺭﻁﻭﺒﺔ ﺍﻝﻨﺴﺒﻴﺔ ﺍﻝﻤﺭﺠﻌﻴﺔ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻌﺎﻤﺔ ﻨﺴﺒﺔ ﺴﺭﻋﺔ ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ‬
‫ﺒﺩﺭﺠﺔ ﺍﻝﺤﺭﺍﺭﺓ ﺍﻝﻤﺫﻜﻭﺭﺓ‬ ‫ﺒﻨﻔﺱ ﺩﺭﺠﺔ ﺍﻝﺤﺭﺍﺭﺓ‬
‫‪1.9 =(100-25) : (100- 25°C /60% RH‬‬ ‫‪25°C /25% RH‬‬
‫)‪60‬‬
‫‪1.5 =(100-40) : (100- 25°C /60% RH‬‬ ‫‪25°C /40% RH‬‬
‫)‪60‬‬
‫‪3.0 =(100-25) : (100- 25°C /75% RH‬‬ ‫‪40°C /75% RH‬‬
‫)‪75‬‬

‫ﻴﻤﻜﻥ ﺍﺴﺘﻌﻤﺎل ﻨﺴﺏ ﺴﺭﻋﺔ ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ ﺒﺸﺭﻭﻁ ﺭﻁﻭﺒﺔ ﻨﺴﺒﻴﺔ ﺃﺨﺭﻯ ﺘﺨﺘﻠﻑ ﻋﻥ ﺍﻝﻘﻴﻡ‬
‫ﺍﻝﻤﺫﻜﻭﺭﺓ ﻓﻲ ﺍﻝﺠﺩﻭل ﺃﻋﻼﻩ‪.‬‬

‫‪ ٤,٧,٢,٢‬ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺠﺎﻫﺯﺓ ﺍﻝﻤﻌﺩﺓ ﻝﻠﺘﺨﺯﻴﻥ ﻓﻲ ﺍﻝﺒﺭﺍﺩ‬


‫‪Finished products intended for storage in a refrigerator‬‬

‫ﺍﻝﻔﺘﺭﺓ ﺍﻝﺯﻤﻨﻴﺔ ﺍﻝﺩﻨﻴﺎ ﺍﻝﺘﻲ‬ ‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ‬ ‫ﻨﻭﻉ ﺍﻝﺩﺭﺍﺴﺔ‬


‫ﺘﻐﻁﻴﻬﺎ ﺍﻝﺒﻴﺎﻨﺎﺕ ﻓﻲ ﺯﻤﻥ‬
‫ﺘﻘﺩﻴﻡ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل‬
‫‪ ٦‬ﺸﻬﻭﺭ )ﺍﻝﺨﻴﺎﺭ ﺃ ﺃﻭ ﺏ(‬ ‫‪5°C ± 3°C‬‬ ‫ﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‬
‫‪ ٦ 25°C ± 2°C/60% RH ± 5% RH‬ﺸﻬﻭﺭ‬ ‫ﻤﺴﺭﻋﺔ‬

‫ﺇﺫﺍ ﺘﻡ ﺘﻌﺒﺌﺔ ﺍﻝﻤﺴﺘﺤﻀﺭ ﺍﻝﻨﻬﺎﺌﻲ ﻓﻲ ﻭﻋﺎﺀ ﻨﺼﻑ ﻨﻔﻭﺫ ‪ ،‬ﻋﻨﺩﻫﺎ ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﻤﻌﻠﻭﻤﺎﺕ ﻤﻨﺎﺴﺒﺔ‬
‫ﺘﺒﻴﻥ ﻜﻤﻴﺔ ﻓﻘﺩﺍﻥ ﺍﻝﻤﺎﺀ‪.‬‬

‫ﻴﺠﺏ ﺘﻘﻴﻴﻡ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺘﺨﺯﻴﻥ ﻓﻲ ﺍﻝﺒﺭﺍﺩ ﺘﺒﻌﺎ ﻝﻠﻘﺴﻡ ﺍﻝﻤﺘﻌﻠﻕ ﺒﺘﻘﻴﻴﻡ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ‬
‫ﺍﻝﻤﺫﻜﻭﺭﺓ ﻓﻲ ﻫﺫﺍ ﺍﻝﺩﻝﻴل‪ ،‬ﺒﺎﺴﺘﺜﻨﺎﺀ ﺍﻝﺫﻱ ﺴﻴﺘﻡ ﺫﻜﺭﻩ ﺃﺩﻨﺎﻩ ﺒﻜل ﻭﻀﻭﺡ ﻭﺼﺭﺍﺤﺔ‪.‬‬

‫ﺇﺫﺍ ﺤﺼل ﺘﺒﺩل ﻤﻠﺤﻭﻅ ﺒﻴﻥ ‪ ٣‬ﻭ‪ ٦‬ﺸﻬﻭﺭ ﻓﻲ ﺍﻝﺩﺭﺍﺴﺔ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺴﺭﻋﺔ ‪ ،‬ﻓﺈﻥ ﺘﺎﺭﻴﺦ‬
‫ﺇﻋﺎﺩﺓ ﺍﻝﻔﺤﺹ ﻴﺠﺏ ﺃﻥ ﻴﺴﺘﻨﺩ ﻋﻠﻰ ﻨﺘﺎﺌﺞ ﺍﻝﺯﻤﻥ ﺍﻝﺤﻘﻴﻘﻲ ﺍﻝﻤﺘﻭﻓﺭﺓ ﻓﻲ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ‬
‫ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‪.‬‬

‫ﺇﺫﺍ ﺤﺼل ﺘﺒﺩل ﻤﻠﺤﻭﻅ ﺨﻼل ﺍﻝﺜﻼﺜﺔ ﺃﺸﻬﺭ ﺍﻷﻭﻝﻰ ﻓﻲ ﺇﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺨﺯﻨﺔ ﺒﺸﺭﻭﻁ‬
‫ﻤﺴﺭﻋﺔ ‪ ،‬ﻓﺈﻥ ﺍﻝﻨﻘﺎﺵ ﻴﺠﺏ ﺃﻥ ﻴﻘﺩﻡ ﺩﻻﺌل ﺘﺸﻴﺭ ﺇﻝﻰ ﺍﻝﺘﺄﺜﻴﺭﺍﺕ ﺍﻝﺘﻲ ﺘﺤﺼل ﻋﻨﺩ ﺘﻌﺭﻴﺽ‬
‫ﺍﻝﻤﺴﺘﺤﻀﺭ ﻝﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﺘﺨﺘﻠﻑ ﻋﻥ ﺍﻝﻤﻨﺼﻭﺹ ﻋﻠﻴﻬﺎ ﻓﻲ ﺍﻝﻌﻨﻭﻨﺔ‪ .‬ﻤﺜﺎل ﻋﻨﺩ ﺸﺤﻥ ﺍﻝﻤﺎﺩﺓ‬
‫ﺃﻭ ﺍﻝﺘﻌﺎﻭل ﻤﻌﻬﺎ‪ .‬ﻫﺫﺍ ﺍﻝﻨﻘﺎﺵ ﻴﻤﻜﻥ ﺃﻥ ﻴﺩﻋﻡ ‪ ،‬ﺇﺫﺍ ﻜﺎﻥ ﻤﻨﺎﺴﺒﺎ‪ ،‬ﻤﻥ ﺨﻼل ﺇﺨﺘﺒﺎﺭﺍﺕ ﺇﻀﺎﻓﻴﺔ‬

‫‪١٨‬‬
‫ﺘﺠﺭﻯ ﻋﻠﻰ ﺘﺤﻀﻴﺭﺓ ﻭﺍﺤﺩﺓ ﻝﻠﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﻝﻤﺩﺓ ﺘﻘل ﻋﻥ ﺜﻼﺜﺔ ﺃﺸﻬﺭ ﻝﻜﻥ ﺒﺘﻜﺭﺍﺭﻴﺔ ﺃﻜﺜﺭ‬
‫ﻝﻺﺨﺘﺒﺎﺭﺍﺕ ﻋﻥ ﺍﻝﺫﻱ ﻴﺘﻡ ﻋﺎﺩﺓ‪ .‬ﻴﻌﺘﺒﺭ ﻏﻴﺭ ﻀﺭﻭﺭﻱ ﺍﻻﺴﺘﻤﺭﺍﺭ ﻓﻲ ﺩﺭﺍﺴﺔ ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ‬
‫ﺨﻼل ﺴﺘﺔ ﺃﺸﻬﺭ ﺇﺫﺍ ﺤﺼل ﺘﺒﺩﻻﺕ ﻤﻠﺤﻭﻅﺔ ﺨﻼل ﺍﻝﺜﻼﺜﺔ ﺃﺸﻬﺭ ﺍﻷﻭﻝﻰ‪.‬‬

‫‪ ٥,٧,٢,٢‬ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺠﺎﻫﺯﺓ ﺍﻝﻤﻌﺩﺓ ﻝﻠﺘﺨﺯﻴﻥ ﻓﻲ ﺍﻝﻤﺠﻤﺩﺓ‬


‫‪Finished products intended for storage in a freezer‬‬

‫ﺍﻝﻔﺘﺭﺓ ﺍﻝﺯﻤﻨﻴﺔ ﺍﻝﺩﻨﻴﺎ ﺍﻝﺘﻲ‬ ‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ‬ ‫ﻨﻭﻉ ﺍﻝﺩﺭﺍﺴﺔ‬


‫ﺘﻐﻁﻴﻬﺎ ﺍﻝﺒﻴﺎﻨﺎﺕ ﻓﻲ ﺯﻤﻥ‬
‫ﺘﻘﺩﻴﻡ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل‬
‫‪ ٦‬ﺸﻬﻭﺭ )ﺍﻝﺨﻴﺎﺭ ﺃ (‬ ‫‪-20°C ± 5°C‬‬ ‫ﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‬
‫‪ ١٢‬ﺸﻬﺭ ﺍﻝﺨﻴﺎﺭ) ﺏ(‬

‫ﺒﺎﻝﻨﺴﺒﺔ ﻝﻠﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺠﺎﻫﺯﺓ ﺍﻝﻤﻌﺩﺓ ﻝﻠﺘﺨﺯﻴﻥ ﻓﻲ ﺍﻝﻤﺠﻤﺩﺓ ‪ ،‬ﻓﺈﻥ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﻴﺠﺏ‬
‫ﺃﻥ ﺘﻌﺘﻤﺩ ﻋﻠﻰ ﻨﺘﺎﺌﺞ ﺒﻴﺎﻨﺎﺕ ﺍﻝﺯﻤﻥ ﺍﻝﺤﻘﻴﻘﻲ ﺍﻝﺘﻲ ﻴﺘﻡ ﺍﻝﺤﺼﻭل ﻋﻠﻴﻬﺎ ﻤﻥ ﺍﻝﺩﺭﺍﺴﺔ ﺒﺸﺭﻭﻁ‬
‫ﺘﺨﺯﻴﻥ ﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‪ .‬ﻓﻲ ﻏﻴﺎﺏ ﺍﻝﺩﺭﺍﺴﺔ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺴﺭﻋﺔ ﻝﻠﻤﺴﺘﺤﻀﺭ ﺍﻝﻨﻬﺎﺌﻲ ﻭﺍﻝﺘﻲ‬
‫ﻴﻌﺩ ﻝﻬﺎ ﺃﻥ ﺘﺨﺯﻥ ﻓﻲ ﺍﻝﻤﺠﻤﺩﺓ ‪ ،‬ﻓﺈﻥ ﺍﻝﻔﺤﻭﺹ ﻴﺠﺏ ﺃﻥ ﺘﺠﺭﻯ ﻋﻠﻰ ﺘﺤﻀﻴﺭﺓ ﻭﺍﺤﺩﺓ‬
‫ﺒﺩﺭﺠﺎﺕ ﺤﺭﺍﺭﺓ ﻤﺭﺘﻔﻌﺔ ) ﻤﺜل ‪ 5°C ± 3°C‬ﺃﻭ ‪ ( 25°C ± 2°C‬ﻭﺫﻝﻙ ﻝﻔﺘﺭﺓ ﺯﻤﻨﻴﺔ ﻤﻨﺎﺴﺒﺔ‬
‫‪ .‬ﻤﺜل ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔ ﺘﻘﺩﻡ ﺒﻴﺎﻨﺎﺕ ﺤﻭل ﺘﺄﺜﻴﺭ ﺘﻌﺭﺽ ﺍﻝﻤﺎﺩﺓ ﻝﻔﺘﺭﺓ ﻗﺼﻴﺭﺓ ﻝﻅﺭﻭﻑ ﺍﻝﻨﻘل‬
‫ﻭﺍﻝﺸﺤﻥ ﻭﺍﻝﺘﻌﺎﻤل ﻤﻊ ﺍﻝﻤﺎﺩﺓ ﺘﺨﺘﻠﻑ ﻋﻥ ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﺼﺭﺡ ﻋﻨﻬﺎ ﻓﻲ ﺍﻝﻌﻨﻭﻨﺔ‪.‬‬

‫‪ ٦,٧,٢,٢‬ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﻨﻬﺎﺌﻴﺔﺍﻝﻤﻌﺩﺓ ﻝﻠﺘﺨﺯﻴﻥ ﺒﺸﺭﻭﻁ ﺃﻗل ﻤﻥ ‪-20°C‬‬


‫‪Finished products intended for storage below -20°C‬‬

‫ﻴﺠﺏ ﻤﻌﺎﻤﻠﺔ ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﻨﻬﺎﺌﻴﺔ ﺍﻝﻤﻌﺩﺓ ﻝﻠﺘﺨﺯﻴﻥ ﺒﺸﺭﻭﻁ ﺃل ﻤﻥ ‪ -20°C‬ﺒﺤﺴﺏ ﻜل‬


‫ﺤﺎﻝﺔ‪.‬‬

‫‪١٩‬‬
‫‪ ٨,٢,٢‬ﺘﻌﻬﺩ ﺍﻝﺜﺒﺎﺕ ‪Stability commitment‬‬

‫ﻋﻨﺩﻤﺎ ﺘﻜﻭﻥ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻝﻠﺘﺤﻀﻴﺭﺍﺕ ﺍﻷﻭﻝﻴﺔ ﻻﺘﻐﻁﻲ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ‬
‫ﺍﻹﺨﺘﺒﺎﺭ ﺍﻝﻤﻘﺘﺭﺤﺔ ﻭﺍﻝﺘﻲ ﺘﻡ ﺍﻝﻤﻭﺍﻓﻘﺔ ﻋﻠﻴﻬﺎ ﺨﻼل ﻓﺘﺭﺓ ﺍﻝﺘﻘﻴﻴﻡ ﻝﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﻋﻨﺩﻫﺎ ﻴﺠﺏ‬
‫ﺘﻘﺩﻴﻡ ﺘﻌﻬﺩ ﻝﻺﺴﺘﻤﺭﺍﺭ ﺒﺈﺠﺭﺍﺀ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺒﻌﺩ ﻤﻨﺢ ﺍﻝﺘﺭﺨﻴﺹ ﺍﻝﻼﺯﻡ ﻤﻥ ﺃﺠل ﺘﺤﻘﻴﻕ‬
‫ﻭﺒﺸﻜل ﻤﺅﻜﺩ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ‪.‬‬

‫ﻋﻨﺩ ﺘﻘﺩﻴﻡ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻝﺜﻼﺙ ﺘﺤﻀﻴﺭﺍﺕ ﺼﻨﺎﻋﻴﺔ ﻴﺘﻡ ﻓﻴﻬﺎ ﺘﻐﻁﻴﺔ ﻤﺩﺓ‬
‫ﺍﻹﺨﺘﺒﺎﺭ ‪ ،‬ﻋﻨﺩﻫﺎ ﻝﻴﺱ ﻤﻥ ﺍﻝﻀﺭﻭﺭﻱ ﺘﻘﺩﻴﻡ ﺘﻌﻬﺩ ﺍﻝﺜﺒﺎﺕ ﺒﻌﺩ ﻤﻨﺢ ﺍﻝﺘﺭﺨﻴﺹ ﺍﻝﻼﺯﻡ ‪ .‬ﺨﻼﻑ‬
‫ﺫﻝﻙ ﻓﺈﻨﻪ ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﺃﺤﺩ ﺍﻝﺘﻌﻬﺩﺍﺕ ﺍﻝﺘﺎﻝﻴﺔ‪:‬‬
‫‪ .١‬ﺇﺫﺍ ﻜﺎﻥ ﺍﻝﻤﻠﻑ ﺍﻝﻤﻘﺩﻡ ﻝﻠﺘﺴﺠﻴل ﻴﺘﻀﻤﻥ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﺜﻼﺙ‬
‫ﺘﺤﻀﻴﺭﺍﺕ ﺼﻨﺎﻋﻴﺔ ﻋﻠﻰ ﺍﻷﻗل ‪ ،‬ﻋﻨﺩﻫﺎ ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﺘﻌﻬﺩ ﻝﻺﺴﺘﻤﺭﺍﺭ ﺒﺘﻠﻙ‬
‫ﺍﻝﺩﺭﺍﺴﺎﺕ ﻝﻠﻭﺼﻭل ﻝﻔﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ‪.‬‬
‫‪ .٢‬ﺇﺫﺍ ﻜﺎﻥ ﺍﻝﻤﻠﻑ ﺍﻝﻤﻘﺩﻡ ﻝﻠﺘﺴﺠﻴل ﻴﺘﻀﻤﻥ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻋﺩﺩ ﺃﻗل ﻤﻥ‬
‫ﺜﻼﺙ ﺘﺤﻀﻴﺭﺍﺕ ﺼﻨﺎﻋﻴﺔ ‪ ،‬ﻋﻨﺩﻫﺎ ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﺘﻌﻬﺩ ﻝﻺﺴﺘﻤﺭﺍﺭ ﺒﺘﻠﻙ‬
‫ﺍﻝﺩﺭﺍﺴﺎﺕ ﻝﻠﻭﺼﻭل ﻝﻔﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﻭﺇﻀﺎﻓﺔ ﺘﺤﻀﻴﺭﺍﺕ ﺼﻨﺎﻋﻴﺔ‬
‫ﻝﻠﻭﺼﻭل ﻝﻤﺠﻤﻭﻉ ﺜﻼﺙ ﺘﺤﻀﻴﺭﺍﺕ ﻭﺃﻥ ﺘﺠﺭﻯ ﻋﻠﻴﻬﺎ ﺩﺭﺍﺴﺎﺕ ﺜﺒﺎﺕ ﻁﻭﻴﻠﺔ‬
‫ﺍﻷﻤﺩ ﻝﻠﻭﺼﻭل ﺇﻝﻰ ﺘﺎﺭﻴﺦ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﺍﻝﻤﻘﺘﺭﺤﺔ ﻓﻲ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﻭﻜﺫﻝﻙ‬
‫ﺘﺘﻤﺔ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺴﺭﻋﺔ ﻝﻤﺩﺓ ﺴﺘﺔ ﺃﺸﻬﺭ‪.‬‬
‫‪ .٣‬ﺇﺫﺍ ﻜﺎﻥ ﺍﻝﻤﻠﻑ ﺍﻝﻤﻘﺩﻡ ﻝﻠﺘﺴﺠﻴل ﻻ ﻴﺘﻀﻤﻥ ﻨﺘﺎﺌﺞ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻝﺜﻼﺙ‬
‫ﺘﺤﻀﻴﺭﺍﺕ ﺼﻨﺎﻋﻴﺔ ‪ ،‬ﻋﻨﺩﻫﺎ ﻴﺠﺏ ﺘﻘﺩﻴﻡ ﺘﻌﻬﺩ ﻝﻺﺴﺘﻤﺭﺍﺭ ﺒﺘﻠﻙ ﺍﻝﺩﺭﺍﺴﺎﺕ‬
‫ﻝﺜﻼﺙ ﺘﺤﻀﻴﺭﺍﺕ ﺼﻨﺎﻋﻴﺔ ﻭﺃﻥ ﺘﺠﺭﻯ ﻋﻠﻴﻬﺎ ﺩﺭﺍﺴﺎﺕ ﺜﺒﺎﺕ ﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ‬
‫ﻝﻠﻭﺼﻭل ﺇﻝﻰ ﺘﺎﺭﻴﺦ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﺍﻝﻤﻘﺘﺭﺤﺔ ﻓﻲ ﻤﻠﻑ ﺍﻝﺘﺴﺠﻴل ﻭﻜﺫﻝﻙ ﺘﺘﻤﺔ‬
‫ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺴﺭﻋﺔ ﻝﻤﺩﺓ ﺴﺘﺔ ﺃﺸﻬﺭ‪.‬‬

‫ﻴﺠﺏ ﺃﻥ ﻴﻜﻭﻥ ﺒﺭﻭﺘﻭﻜﻭل ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺘﺒﻊ ﻓﻲ ﺘﻌﻬﺩ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻁﻭﻴﻠﺔ ﺍﻷﻤﺩ ﻫﻭ ﻨﻔﺴﻪ‬
‫ﺍﻝﻤﺴﺘﻌﻤل ﻝﻠﺘﺤﻀﻴﺭﺍﺕ ﺍﻝﺘﺠﺭﻴﺒﻴﺔ ﺍﻷﻭﻝﻴﺔ ‪ ،‬ﻤﺎ ﻋﺩﺍ ﺒﻌﺽ ﺍﻝﺤﺎﻻﺕ ﺍﻝﺘﻲ ﻴﻤﻜﻥ ﺘﺒﺭﻴﺭﻫﺎ ﻋﻠﻤﻴﺎ‪.‬‬

‫ﻋﻨﺩﻤﺎ ﻴﺘﻡ ﺇﺠﺭﺍﺀ ﺩﺭﺍﺴﺔ ﺍﻝﺜﺒﺎﺕ ﻓﻲ ﺸﺭﻭﻁ ﻤﺘﻭﺴﻁﺔ ﻜﺤﺎﺠﺔ ﺒﺴﺒﺏ ﺤﺩﻭﺙ ﺘﺒﺩﻻﺕ ﺠﻭﻫﺭﻴﺔ‬
‫ﺃﺜﻨﺎﺀ ﻓﺘﺭﺓ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻤﺴﺭﻋﺔ ﻝﺘﺤﻀﻴﺭﺍﺕ ﺃﻭﻝﻴﺔ )ﺘﺠﺭﻴﺒﻴﺔ( ‪ ،‬ﻴﻤﻜﻥ ﺍﺴﺘﻜﻤﺎل ﺇﺠﺭﺍﺀ ﺍﻝﺩﺭﺍﺴﺔ‬
‫ﺍﻝﺜﺒﺎﺕ ﻋﻠﻰ ﺘﺤﻀﻴﺭﺍﺕ ﻤﻠﺘﺯﻤﺔ ) ﺍﻝﺘﻲ ﺘﻡ ﺍﻝﺘﻌﻬﺩ ﺒﺘﻘﺩﻴﻡ ﻨﺘﺎﺌﺠﻬﺎ( ﺇﻤﺎ ﺒﺎﺘﺒﺎﻉ ﺍﻝﺩﺭﺍﺴﺔ ﻓﻲ‬
‫ﺸﺭﻭﻁ ﻤﺴﺭﻋﺔ ﺃﻭ ﻤﺘﻭﺴﻁﺔ‪ .‬ﻋﻠﻰ ﺃﻴﺔ ﺤﺎل ﺇﺫﺍ ﺤﺼل ﺘﺒﺩل ﻤﻬﻡ ﻓﻲ ﺸﺭﻭﻁ ﻤﺴﺭﻋﺔ ﻋﻨﺩﻫﺎ‬
‫ﻴﺠﺏ ﺍﺴﺘﻜﻤﺎل ﺍﻝﺩﺭﺍﺴﺔ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺘﻭﺴﻁﺔ‪.‬‬

‫‪٢٠‬‬
‫‪ ٩,٢,٢‬ﺍﻝﺘﻘﻴﻴﻡ ‪Evaluation‬‬
‫ﻴﺠﺏ ﺇﻋﺘﻤﺎﺩ ﻤﻨﻬﺞ ﻤﻨﻅﻡ ﻓﻲ ﺘﻘﺩﻴﻡ ﻭﺘﻘﻴﻴﻡ ﻤﻌﻠﻭﻤﺎﺕ ﺍﻝﺜﺒﺎﺕ‪ ،‬ﻭﺍﻝﺘﻲ ﻴﺠﺏ ﺃﻥ ﺘﺘﻀﻤﻥ ﺒﺤﺴﺏ‬
‫ﺍﻝﺤﺎﻝﺔ ﻨﺘﺎﺌﺞ ﺇﺨﺘﺒﺎﺭﺍﺕ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﺍﻝﻔﻴﺯﻴﺎﺌﻴﺔ ﻭﺍﻝﻜﻴﻤﻴﺎﺌﻴﺔ ﻭﺍﻝﺤﻴﻭﻴﺔ ﻭﺍﻝﺠﺭﺜﻭﻤﻴﺔ‪ ،‬ﻤﻊ ﺍﻷﺨﺫ‬
‫ﺒﻌﻴﻥ ﺍﻻﻋﺘﺒﺎﺭ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﻤﺘﻌﻠﻘﺔ ﺒﺎﻝﺸﻜل ﺍﻝﺼﻴﺩﻻﻨﻲ ) ﻤﺜل ﺴﺭﻋﺔ ﺍﻹﻨﺤﻼﻝﻴﺔ ﻝﻸﺸﻜﺎل‬
‫ﺍﻝﺼﻴﺩﻻﻨﻴﺔ ﺍﻝﻔﻤﻭﻴﺔ ﺍﻝﺼﻠﺒﺔ(‬
‫ﺇﻥ ﺍﻝﻬﺩﻑ ﻤﻥ ﺩﺭﺍﺴﺎﺕ ﺍﻝﺜﺒﺎﺕ ﻫﻭ ﻝﻠﺘﺄﻜﺩ ‪ ،‬ﺒﺎﻻﻋﺘﻤﺎﺩ ﻋﻠﻰ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﺘﻲ ﺘﺠﺭﻯ ﻋﻠﻰ ﺍﻷﻗل‬
‫ﻝﺘﺤﻀﻴﺭﺘﻴﻥ ﺃﻭ ﺜﻼﺙ ﺘﺤﻀﻴﺭﺍﺕ ﻤﻥ ﺍﺍﻝﻤﺴﺘﺤﻀﺭ ﺍﻝﻨﻬﺎﺌﻲ ﻭﺘﻘﻴﻴﻡ ﻤﻌﻠﻭﻤﺎﺕ ﺍﻝﺜﺒﺎﺕ ) ﺘﺘﻀﻤﻥ‬
‫ﺒﺤﺴﺏ ﺍﻝﻀﺭﻭﺭﺓ ﻨﺘﺎﺌﺞ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺍﻝﻔﻴﺯﻴﺎﺌﻴﺔ ﻭﺍﻝﻜﻴﻤﻴﺎﺌﻴﺔ ﻭﺍﻝﺤﻴﻭﻴﺔ ﻭﺍﻝﺠﺭﺜﻭﻤﻴﺔ ( ‪ ،‬ﻓﺘﺭﺓ‬
‫ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﺘﻨﻁﺒﻕ ﻋﻠﻰ ﺠﻤﻴﻊ ﺍﻝﺘﺤﻀﻴﺭﺍﺕ ﺍﻝﺘﻲ ﺴﻴﺘﻡ ﺘﺼﻨﻴﻌﻬﺎ ﻤﺴﺘﻘﺒﻼ ﺒﺎﺘﺒﺎﻉ ﻨﻔﺱ‬
‫ﻁﺭﻴﻘﺔ ﺍﻝﺘﺼﻨﻴﻊ ﻝﻠﻤﺴﺘﺤﻀﺭ ﺍﻝﺠﺎﻫﺯ ﻭﺘﺤﺕ ﺸﺭﻭﻁ ﻤﻤﺎﺜﻠﺔ ‪.‬ﺇﻥ ﺩﺭﺠﺔ ﺍﻝﺘﺒﺎﻴﻥ ﻭﺍﻹﺨﺘﻼﻑ ﻓﻲ‬
‫ﺍﻝﺘﺤﻀﻴﺭﺍﺕ ﺍﻝﻔﺭﺩﻴﺔ ﻴﺅﺜﺭ ﻓﻲ ﺍﻝﺜﻘﺔ ﺒﺄﻥ ﺍﻝﺘﺤﻀﻴﺭﺍﺕ ﺍﻝﺘﻲ ﺴﻴﺘﻡ ﺇﻨﺘﺎﺠﻬﺎ ﻤﺴﺘﻘﺒﻼ ﺴﺘﺒﻘﻰ ﻀﻤﻥ‬
‫ﺍﻝﻤﻭﺍﺼﻔﺎﺕ ﻁﻴﻠﺔ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ‪.‬‬
‫ﺇﺫﺍ ﺃﻅﻬﺭﺕ ﺍﻝﻨﺘﺎﺌﺞ ﺘﺨﺭﺏ ﻗﻠﻴل ﻭﺍﺨﺘﻼﻑ ﻗﻠﻴل ﺠﺩﺍ ﻴﻤﻜﻥ ﻤﻼﺤﻅﺘﻪ ﻋﻨﺩ ﺍﻝﻨﻅﺭ ﻓﻲ ﻨﺘﺎﺌﺞ‬
‫ﺍﻝﺩﺭﺍﺴﺔ ﺒﺤﻴﺙ ﻴﺘﻡ ﻤﻨﺢ ﺍﻝﻤﻭﺍﻓﻘﺔ ﻋﻠﻰ ﺘﺎﺭﻴﺦ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﺍﻝﻤﻁﻠﻭﺏ ‪ .‬ﻓﻲ ﻤﺜل ﺘﻠﻙ ﺍﻝﺤﺎﻻﺕ‬
‫‪ ،‬ﻓﺈﻨﻪ ﻤﻥ ﻏﻴﺭ ﺍﻝﻀﺭﻭﺭﻱ ﻹﺠﺭﺍﺀ ﺘﺤﻠﻴل ﺇﺤﺼﺎﺌﻲ ؛ﺇﺫﺍ ﺜﺒﺕ ﺒﺄﻥ ﺍﻝﺤﺫﻑ ﻤﻘﻨﻌﺎ ‪.‬‬
‫ﺇﻥ ﺍﻝﻤﻨﺤﻰ ﻝﺘﺤﻠﻴل ﺍﻝﻨﺘﺎﺌﺞ ﺒﺸﻜل ﻜﻤﻲ ﻝﻠﻤﻭﺍﺩ ﺍﻝﺘﻲ ﻴﻤﻜﻥ ﺃﻥ ﺘﺘﺒﺩل ﻤﻊ ﺍﻝﺯﻤﻥ ﻭﺫﻝﻙ ﻝﺘﺤﺩﻴﺩ‬
‫ﺍﻝﺯﻤﻥ ﺍﻝﺘﻲ ﺘﺸﻜل ﻓﻴﻪ ﺍﻝﺜﻘﺔ ﻓﻲ ﺍﻝﻨﺘﺎﺌﺞ ﺒﺎﺘﺠﺎﻩ ﻭﺍﺤﺩ ﻨﺴﺒﺔ ‪ %٩٥‬ﻭﺒﺄﻥ ﺍﻝﻤﻨﺤﻨﻰ ﺍﻝﻭﺴﻁﻲ‬
‫ﻴﺘﻘﺎﻁﻊ ﻤﻊ ﻤﺘﻁﻠﺒﺎﺕ ﺍﻝﻘﺒﻭل ﺍﻝﻘﻴﺎﺴﻲ‪ .‬ﺇﺫﺍ ﺒﻴﻨﺕ ﺍﻝﻨﺘﺎﺌﺞ ﺒﺄﻥ ﺍﻹﺨﺘﻼﻓﺎﺕ ﻤﻥ ﺘﺤﻀﻴﺭﺓ ﻝﺘﺤﻀﻴﺭﺓ‬
‫ﺼﻐﻴﺭ ﻋﻨﺩﻫﺎ ﻴﻜﻭﻥ ﻤﻥ ﺍﻝﻤﻔﻀل ﺠﻤﻊ ﺍﻝﺒﻴﺎﻨﺎﺕ ﻝﻠﻭﺼﻭل ﻝﺘﻘﺩﻴﺭ ﺇﺠﻤﺎﻝﻲ‪ .‬ﻴﻤﻜﻥ ﺘﺤﻘﻴﻕ ﺫﻝﻙ‬
‫ﻤﻥ ﺨﻼل ﺘﻁﺒﻴﻕ ﺇﺨﺘﺒﺎﺭﺍﺕ ﺇﺤﺼﺎﺌﻴﺔ ﻤﻨﺎﺴﺒﺔ )ﻤﺜل ‪ ،.‬ﺤﺩﻭﺩ ﻗﻴﻡ ﺍﻝﺭﻓﺽ ﺫﻭ ﺍﻷﻫﻤﻴﺔ ﺇﺫﺍ ﻜﺎﻨﺕ‬
‫ﺃﻜﺜﺭ ﻤﻥ ‪.( ٠,٢٥‬‬
‫ﺇﻥ ﺃﻱ ﺘﻘﻴﻴﻡ ﻴﺠﺏ ﺃﻥ ﻴﻐﻁﻲ ﻝﻴﺱ ﻓﻘﻁ ﺍﻝﻤﻌﺎﻴﺭﺓ ‪ ،‬ﺒل ﻴﺠﺏ ﺃﻥ ﻴﻐﻁﻲ ﺃﻴﻀﺎ ﻤﻭﺍﺩ ﺍﻝﺘﺨﺭﺏ‬
‫ﻭﺍﻝﻌﻭﺍﻤل ﺍﻝﻤﺸﺎﺭﻜﺔ ﺍﻷﺨﺭﻯ ‪.‬‬

‫‪ ١٠,٢,٢‬ﺘﺼﺭﻴﺢ‪ /‬ﺍﻝﻌﻨﻭﻨﺔ ‪Statements/Labelling‬‬

‫ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ )ﺤﺭﺍﺭﺓ ‪ ،‬ﻀﻭﺀ ‪ ،‬ﺭﻁﻭﺒﺔ( ﺍﻝﻤﺼﺭﺡ ﺒﻬﺎ ﻴﺠﺏ ﺃﻥ ﺘﺴﺘﻨﺩ ﻋﻠﻰ ﺩﻝﻴل ﺘﺼﺭﻴﺢ‬
‫ﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﺩﻭﺍﺌﻴﺔ – ﺍﻝﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ‪.‬‬
‫ﺇﻥ ﺍﺴﺘﻌﻤﺎل ﺘﻌﺎﺒﻴﺭ ﻤﺜل ﺍﻝﺸﺭﻭﻁ ﺍﻝﻁﺒﻴﻌﻴﺔ ﺃﻭ ﺤﺭﺍﺭﺓ ﺍﻝﻐﺭﻓﺔ ﻫﻭ ﻏﻴﺭ ﻤﻘﺒﻭل‪.‬‬

‫‪٢١‬‬
‫ﻤﻠﺤﻕ ‪Annex I‬‬

‫ﺘﻌﺘﺒﺭ ﺍﻝﻤﺎﺩﺓ ﺍﻝﻔﻌﺎﻝﺔ ﺜﺎﺒﺘﺔ ﺇﺫﺍ ﺒﻘﻴﺕ ﻤﺤﺎﻓﻅﺔ ﻋﻠﻰ ﺍﻝﻤﻭﺍﺼﻔﺎﺕ ﺍﻝﻤﻌﺭﻓﺔ ﺃﻭ ﺍﻝﺼﺎﺩﺭﺓ ﻋﻥ‬
‫ﺍﻝﺴﻠﻁﺎﺕ ﺍﻝﺼﺤﻴﺔ ﻝﻤﺩﺓ ﻻﺘﻘل ﻋﻥ ﻋﺎﻤﻴﻥ ﻋﻨﺩ ﺘﺨﺯﻴﻨﻬﺎ ﺒﺸﺭﻭﻁ ‪ 25°C /60% RH‬ﺃﻭ‬
‫ﺒﺸﺭﻭﻁ ‪ 30°C /65% RH‬ﻭﻜﺫﻝﻙ ﻝﻤﺩﺓ ﺴﺘﺔ ﺃﺸﻬﺭ ﺒﺸﺭﻭﻁ ‪. 40°C /75% RH‬‬

‫ﻤﻠﺤﻕ ‪Annex II‬‬

‫ﺍﺴﺘﺨﻼﺹ ﺍﻝﻨﺘﺎﺌﺞ‬

‫ﺇﺫﺍ ﻜﺎﻨﺕ ﻨﺘﺎﺌﺞ ﺍﻝﺯﻤﻥ ﺍﻝﺤﻘﻴﻘﻲ ﺍﻝﻤﺩﻋﻤﺔ ﺒﺩﺭﺍﺴﺎﺕ ﻗﺩ ﺘﻤﺕ ﺒﺸﺭﻭﻁ ﺘﺨﺯﻴﻥ ﻤﺴﺭﻋﺔ ﺃﻭ‬
‫ﻤﺘﻭﺴﻁﺔ ‪ ،‬ﻓﺈﻥ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ‪/‬ﻋﻤﺭ ﺍﻝﺩﻭﺍﺀ ﻋﻠﻰ ﺍﻝﺭﻑ ﻴﻤﻜﻥ ﺃﻥ ﺘﻤﺩﺩ ﻝﻔﺘﺭﺓ ﺃﻁﻭل ﻤﻥ‬
‫ﺩﺭﺍﺴﺎﺕ ﺍﻝﺯﻤﻥ ﺍﻝﺤﻘﻴﻘﻲ‪ .‬ﻋﻤﺭ ﺍﻝﺩﻭﺍﺀ ﻋﻠﻰ ﺍﻝﺭﻑ ﺃﻭ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ ﺍﻹﺨﺘﺒﺎﺭ ﺍﻝﻤﺴﺘﺨﻠﺼﺔ ﺃﻭ‬
‫ﺍﻝﻤﺴﺘﻨﺘﺠﺔ) ﺍﻝﻤﺘﻭﻗﻌﺔ( ﻴﻤﻜﻥ ﺃﻥ ﺘﻜﻭﻥ ﻀﻌﻑ ﺍﻝﻔﺘﺭﺓ ﺍﻝﺯﻤﻨﻴﺔ ﻭﺫﻝﻙ ﺒﺎﻻﻋﺘﻤﺎﺩ ﻋﻠﻰ ﺯﻤﻥ‬
‫ﺍﻝﺘﻐﻴﻴﺭ‪ ،‬ﺍﻻﺨﺘﻼﻑ ﻓﻲ ﺍﻝﻨﺘﺎﺌﺞ‪ ،‬ﺸﺭﻭﻁ ﺍﻝﺘﺨﺯﻴﻥ ﺍﻝﻤﻘﺘﺭﺤﺔ ﻭﻜﻤﻴﺔ ﺍﻝﺘﺤﺎﻝﻴل ﺍﻹﺤﺼﺎﺌﻴﺔ‬
‫ﺍﻝﻤﻨﺠﺯﺓ‪.‬‬

‫ﻤﻠﺤﻕ‪Annex III‬‬
‫ﻤﺭﺘﺴﻡ ﺸﺠﺭﺓ ﺍﻹﺤﺘﻤﺎﻻﺕ‬

‫ﻴﻭﻀﺢ ﺍﻝﻤﺭﺘﺴﻡ ﺍﻝﻤﺭﻓﻕ ﺍﻹﺤﺘﻤﺎﻻﺕ ﺍﻝﻤﺨﺘﻠﻔﺔ ﺍﻝﻤﺘﻭﻗﻌﺔ ﻝﺘﻘﻴﻴﻡ ﺍﻝﻨﺘﺎﺌﺞ ﻝﺘﻘﺩﻴﺭ ﻓﺘﺭﺓ ﺇﻋﺎﺩﺓ‬
‫ﺍﻹﺨﺘﺒﺎﺭ ﺃﻭ ﻋﻤﺭ ﺍﻝﺩﻭﺍﺀ ﻋﻠﻰ ﺍﻝﺭﻑ ﻝﻠﻤﻭﺍﺩ ﺍﻝﻔﻌﺎﻝﺔ ﺃﻭ ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﻨﻬﺎﺌﻴﺔ )ﺒﺎﺴﺘﺜﻨﺎﺀ‬
‫ﺍﻝﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻝﻤﺠﻤﺩﺓ(‪.‬‬

‫‪٢٢‬‬
‫  ول أو أر   درات ات‬
‫('& ‪#$%‬؛  ة إدة أو  اواء  اف‬

‫ا‪ ,- ).‬؛‬ ‫‪ )*+‬وا‪  $‬ا  ‪  .5%‬ة ‪/0' /12 )34‬‬


‫ا ‪ :*1‬ا‪ )'&.  789‬ا‪/*' 46‬‬
‫‪$'*%‬‬
‫ا  ‪&B%‬د إ آ) ‪A‬وط ا ?>'‪ /‬و‪ *+‬آ‪)*;< :‬‬
‫‪:C D4 :02-‬‬

‫‪%‬ل '  ا‪2‬وط ا‪ )D‬ة ‪ ٦‬أ‪,A‬‬


‫(‬
‫أ‪,F‬ت ا‪  $‬ا‪ )'&.‬ا‪:46‬‬
‫‪ -١‬م و&د ‪ *5%‬أو ‪ 4 :*+ *5%‬ا>‪/4‬‬
‫‪ -٢‬م و&د ا< ‪L‬ف أو ا< ‪L‬ف ‪:*+‬‬
‫‪/*$3M B‬‬
‫أ‪,F‬ت ا‪  $‬ا‪:)D‬‬
‫‪ -٣‬م و&د ‪ *5%‬أو ‪ 4 :*+ *5%‬ا>‪/4‬‬
‫‪ -٤‬م و&د ا< ‪L‬ف أو ا< ‪L‬ف ‪:*+‬‬
‫‪/*$3M B‬‬
‫ا ‪ :*1‬ا‪  789‬دة ‪ *Q‬وري‬
‫‪Y= up to 2X,but not exceeding‬‬
‫‪X+12 months ,‬‬
‫‪Or if refrigerated,‬‬
‫‪Y= up to 1.5X, but not exceeding‬‬
‫‪X+6 months‬‬
‫‪  =Y‬ة إدة ا‪ <9‬ر أو  اواء  اف‬
‫‪ =X‬ا‪ S‬ة ا  ‪   ,*.5%‬ارا) ا‪ )'&.‬ا‪46‬‬

‫‪%‬ل ‪  ,4‬ا‪2‬وط ا‪L< )D‬ل ‪ ٣‬أ‪,A‬‬


‫‪B‬‬

‫‪B4‬ة  ?>'‪  /‬ااد‬

‫‪٢٣‬‬

You might also like